

































































































































































































































































































































































































































































disease	 and	 GBS-associated	 mortality	 since	 the	 first	 introduction	 of	 guidelines	 in	
1996.	 However,	 there	 is	 much	 debate	 about	 the	 efficacy	 of	 IAP	 protection	 and	 a	




National	 Screening	 Committee	 examined	 the	 evidence	 for	 the	 prevention	 of	 GBS	
disease	 and,	 in	 contrast	 to	 the	 USA,	 recommended	 that	 routine	 screening	 of	 all	
pregnant	women	should	not	be	 the	part	of	UK	antenatal	 care.(3)	 In	 resource-poor	
countries	 IAP	 use	 poses	 additional	 logistical	 and	 financial	 problems	 and	 is	 poorly	
implemented.(10,	11)	
A	maternal	vaccine	would	be	effective	in	preventing	EO-	and	LO-GBS	disease	
via	 placental	 anti-GBS	 antibody	 transfer,	 as	 well	 as	 protecting	 the	mother	 against	
puerperal	 GBS	 sepsis.	 There	 are	 several	 capsular	 polysaccharide	 (CPS)	 conjugate	
vaccine	candidates	for	maternal	vaccination	in	development	to	prevent	both	EO-	and	
LO-GBS	disease.	These	CPS-conjugate	vaccines	 include	serotypes	(STs)	 Ia,	 Ib	and	III,	
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based	on	epidemiological	data	from	the	UK,	USA	and	South	Africa.(12,	13)	However,	
several	 obstacles	 exist	 in	moving	 the	most	 advanced	 vaccine	 into	 phase	 III	 clinical	
trials.	The	first	is	that,	given	the	relative	rarity	of	GBS	disease	in	Europe	and	the	USA,	
large	numbers	of	 infants	would	need	to	be	recruited	to	determine	vaccine	efficacy	
(at	an	 incidence	rate	of	1/1000	live	births	 it	 is	estimated	that	60,000	infants	would	
be	required	to	show	an	effective	vaccine).	Secondly,	there	is	practically	no	evidence	
outside	 of	 the	 USA,	 Europe	 and	 South	 Africa	 regarding	 disease-causing	 and	




are	 currently	 no	 internationally	 recognised	 standards	 from	 which	 to	 interpret	
individual	study	results.	
As	 colonisation	 is	 the	 prerequisite	 for	 EO-GBS	 disease,	 this	 thesis	 seeks	 to	
introduce	 studies	 that	 attempt	 to	 address	 the	 efficacy	 of	 maternal	 antibody	 in	





































Although	 the	 epidemiology	 of	 GBS	 in	 high-income	 countries	 is	 well	
documented,	its	contribution	to	the	burden	of	neonatal	infection	in	LMIC	has	proven	




STs	 of	 disease-causing	 isolates	 (22,	 24,	 26)	 and	 a	 random	 effects	 meta	 analysis	
demonstrated	 GBS	 ST	 III,	 Ia	 and	 V	 accounted	 for	 84%	 of	 EO-	 and	 96%	 of	 LO-GBS	
disease	in	African	countries,	although	high	heterogeneity	(I2	of	99.7%)	prevents	any	
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Berkely	et	al.	 included	all	 children	admitted	with	 fever	between	August	1998	and	Juiy	2002;	Gray	et	al.	 included	all	children	
with	a	positive	blood	culture	for	GBS	between	May	2004	and	June	2005;	Madzinvandiha	et	al.	included	all	positive	GBS	cultures	




Under-identification	 and	 under-reporting	 of	 cases	 and	 deaths	 appears	 very	
likely	 in	 some	study	 settings,	especially	where	 it	 is	difficult	 to	access	healthcare.	A	
substantial	 proportion	 of	 births	 in	 sub–Saharan	 Africa	 (42-65%),	 India	 (53%)	 and	
Bangladesh	(85%)	 for	example,	occur	outside	health	 institutions.	 In	contrast,	South	
Africa,	which	 reports	 one	 of	 the	 highest	 incidences,	 also	 has	 a	 high	 proportion	 of	
hospital-based	births	(89%).(28)	Despite	GBS	colonisation	rates	in	the	Gambia	in	the	
NOTE: Weights are from random effects analysis
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To	estimate	 the	 true	burden	of	GBS	disease,	 it	may	be	useful	 to	determine	
the	maternal	colonisation	rate	by	country,	as	maternal	colonisation	is	the	main	risk	
factor	 for	 EO-GBS	 disease.	 In	 contrast	 to	 GBS	 invasive	 disease	 incidence	 studies,	
maternal	 GBS	 colonisation	 studies	 reported	 similar	 colonisation	 rates	 to	 those	 of	
high-income	 countries	 (Middle	 East/North	 Africa,	 22%;	 Asia/Pacific,	 19%;	 Sub-



























































































































































































































mucosa	 through	 contact	 with	 maternal	 vaginal/rectal	 secretions	 at	 the	 time	 of	
birth.(67)	However,	Butter	and	De	Moor	also	demonstrated	 infant	nasopharyngeal	
colonisation	at	 the	 same	 time	as	GBS	was	cultured	 from	the	mother’s	breast	milk,	
suggesting	 this	 as	 another	mechanism	 of	 acquisition.(68)	 Despite	 this	 finding,	 the	
majority	of	breastfed	infants	of	mothers	colonised	with	GBS	do	not	develop	LO-GBS	
disease	 (69),	 even	after	proven	GBS	mastitis	 and	 several	months	of	breastfeeding.	
Breast	milk	 is	 known	 to	 have	many	 protective	 properties,	 including	 antibody	 that	
should	protect	infants	from	both	EO-	and	LO-GBS	disease.(40)	
Therefore,	 there	appears	 to	be	a	contradiction	between	 the	possibility	 that	
	 31	
breast	milk	might	 cause	 LO-GBS	 disease	 in	 some	 infants	 yet	 protects	 the	majority	






































































































































































The	 importance	 of	 maternally-derived	 antibody	 in	 preventing	 GBS	 disease	
was	first	demonstrated	over	30	years	ago	by	the	 increased	risk	of	 infant	disease	 in	


















































infants	 from	 EO-GBS	 disease.	 The	 past	 30	 years	 have	 been	 spent	 in	 developing	 a	
vaccine	to	be	given	in	pregnancy	to	elicit	high	levels	of	functional,	GBS	ST-specific	IgG	
that	 would	 cross	 the	 placenta	 and	 protect	 neonates	 from	 disease.(137,	 138)	 It	 is	
estimated	 that	 a	 pentavalent	 vaccine	 containing	GBS	 STs	 Ia,	 Ib,	 II,	 III	 and	V	would	
cover	94-100%	of	invasive	isolates	globally	and	a	trivalent	vaccine	that	would	cover	




order	 to	 assess	 vaccine	 efficacy	 in	 preventing	 neonatal	 disease,	 antibody	
concentrations	must	be	determined	that	confer	protection	from	disease.	However,	
determining	a	protective	antibody	concentration	is	not	easily	achieved,	as	protective	
antibody	 concentrations	 vary	 by	 organism	 (116),	 by	 GBS	 ST	 (139,	 140)	 and	 the	
assessment	of	immunogenicity	varies	by	research	methods.(116,	139)		
The	 association	 between	 GBS	 ST-specific	 capsular	 antibody	 concentrations	
and	 invasive	GBS	disease	 in	 newborns	was	 initially	 characterised	 in	 1976	by	Baker	
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and	 colleagues.(115)	 In	 the	 majority	 of	 subsequent	 studies	 lower	 GBS	 ST-specific	
capsular	 antibodies	were	 found	 in	 infants	with	 EO-	 and	 LO-GBS	 disease	 compared	
with	 controls.(141,	 142)	 Different	 specific	 antibody	 concentrations	 that	 could	 be	
associated	with	 protection	 from	disease	 have	 been	 defined	 in	 different	 studies	 as	
well	as	for	different	GBS	STs	(Table	2).	In	a	meta-analysis	undertaken	to	compare	the	
proportions	 of	 cases	 and	 controls	 with	 antibody	 levels	 ≥2	 μg/mL,	 the	 odds	 of	
invasive	 GBS	 disease	 was	 6.56	 (95%	 CI:	 2.10–20.55)	 and	 2.38	 (95%	 CI:	 1.20–4.70)	
times	greater	in	infants	whose	mothers	had	antibody	levels	<2	μg/mL	for	GBS	STs	III	
and	Ia,	respectively.(143)	A	threshold	of	1	μg/mL	has	also	recently	been	proposed	as	
a	 correlate	 of	 protection	 against	 disease	 caused	 by	 GBS	 STs	 Ia	 and	 III.(116)	
Thresholds	 are	 much	 higher	 in	 other	 large	 studies	 including	 the	 DEVANI	 project,	
based	on	European	sera	(144),	but	there	has	been	significant	controversy	regarding	
appropriate	methods	 to	 be	 used	 to	measure	 the	 antibody	 in	 order	 to	 derive	 such	
thresholds	 reliably.(145)	A	 recent	study	 from	South	Africa	suggested	that	maternal	
concentrations	of	>3μg/mL	for	GBS	STIa	and	>1μg/mL	for	GBS	STV	were	associated	
with	 significantly	 reduced	 maternal	 colonisation	 with	 these	 GBS	 STs	 (Table	 2).	
Further,	 the	 authors	 suggested	 that	 the	 opsonophagocytosis	 killing	 (OPkA)	 titre	
correlated	more	strongly	with	decreased	rectovaginal	acquisition	of	GBS,	 indicating	
the	 need	 for	 both	 a	 quantitative	 and	 a	 functional	 assessment	 of	 antibody	 when	
estimating	 protection.(146)	 Interpretation	 of	 all	 of	 these	 results	 is	 difficult	 due	 to	































USA	 1979	 OPkA	 STIII	≥10μg/mL	 2.0	log10	reduction	in	
CFU/mL	compared	to	
antibody	deficient	sera	
Baker	et	al(83)		 USA	 2003	 OPkA	 STIII	≥1μg/mL	 >1.0	log10	reduction	in	
CFU/mL	



































































A	 major	 barrier	 to	 the	 conduct	 of	 efficacy	 trials	 -	 which	 would	 have	 to	
measure	prevention	of	invasive	neonatal	GBS	disease	as	the	primary	endpoint-	is	the	
large	sample	size	required,	as	described	above.	As	an	alternative,	a	vaccine	could	be	
licenced	 based	 on	 immunogenicity	 data,	 if	 a	 threshold	 of	 protective	 antibody	was	
defined.		




the	antibody	 to	neutralise	GBS.	Therefore,	an	ELISA	alone	may	not	be	 sufficient	 in	
predicting	 functional	 immunity	 from	GBS	 infection.(143)	A	possible	 solution	 to	 this	
may	 be	 the	 development	 of	 an	 effective	 functional	 antibody	 assay	 that	 could	 be	
used	 as	 an	 in	 vitro	 correlate	 of	 protection.	 An	 example	 of	 this	 is	 the	
opsonophagocytosis	killing	assay	(OPkA)	(148,	152),	which	mimics	the	in	vivo	process	




and	 require	 large	 volumes	 of	 test	 sera.	 Reliance	 on	 human	 donor	 phagocytes	
introduces	 an	 extra	 variable,	 though	 this	 can	 be	 addressed	 with	 the	 use	 of	 the	
human	 phagocytic	 cell	 line	 human	 promyelocytic	 leukaemia	 cells	 (HL-60).(154)	 An	
OPkA	that	measures	the	uptake	of	fluorescently-labelled	bacteria	by	flow	cytometry	
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could	potentially	 substitute	 for	a	 conventional	OPkA	 requiring	cumbersome	colony	
counts.(155)	 A	 fluorescence	 opsonophagocytosis	 assay	 (fOPA)	 has	 also	 been	
developed	that	measures	both	the	uptake	of	bacteria	and	the	oxidative	burst	activity	
of	 the	 HL-60	 cells	 in	 a	 96-well	 format.(156)	 For	 large	 seroepidemiological	 studies	
however,	 both	 the	 OPkA	 and	 fOPA	 are	 still	 too	 laborious	 and	 require	 too	 much	
serum	 volume	 from	each	 vaccinee.	 This	 is	 a	 critical	 issue	 in	 studies	where	 sample	
volume	 is	 at	 a	 premium,	 such	 as	 in	 neonatal	 studies.	 Other	 assays,	 including	 an	
antibody-mediated	 complement	 C3b/iC3b	 deposition	 assay	 (125)	 have	 been	
















1.	 GBS	 colonisation	 in	 The	Gambia	 is	 predominantly	 due	 to	 ST	 Ia,	 Ib,	 III	 and	 V	
(addressed	in	specific	aim	1);		




















the	 complement	 deposition	 assay	 in	 order	 to	 determine	 if	 a	 concentration	 of	
antibody	exists	above	which	an	infant	is	no	longer	colonised	with	GBS.	
We	 postulate	 that	 higher	 concentrations	 of	 antibody	 bound	 to	 complement	
determine	 infant	 colonisation	 by	 promoting	 increased	 opsonophagocytic	 killing.	 It	 is		
anticipated	that	there	will	be	an	antibody	threshold	above	which	an	infant	is	no	longer	















































This	 work	 represents	 a	 prospective	 cohort	 study	 of	 pregnant	 women	
attending	 ANC	 in	 the	 Banjul	 area	 of	 The	 Gambia	 and	 their	 infants	 (0-89	 days)	 for	
assessment	 of	 GBS	 colonisation	 and	 GBS	 ST-specific	 antibody	 in	 cord	 and	 infant	




result	 or	 by	 rapid	 test	 at	 32	 weeks.	 HIV-positive	 mothers	 were	 excluded	 from	
enrolment	because	of	 the	effect	of	HIV	on	 the	maternal	 immune	system.	Mothers	
were	required	to	give	birth	at	one	of	the	health	facilities.	Rectovaginal	swabs	were	
taken	 in	 labour	 for	maternal	 GBS	 colonisation	 and	 cord	 blood	 sample	 at	 birth	 for	
functional	 antibody	 testing.	 Infant	 nasopharyngeal	 and	 rectal	 swabs	 and	maternal	


































Inclusion	criteria:		- Breastfeeding	women		- age	18-45	years	- pregnancy	over	32	weeks	gestation		- deemed	low	risk	singleton	pregnancy	(no	evidence	of	pre-eclampsia,	
cardiomyopathy,	maternal	gestational	diabetes,	placenta	praevia,	twin	
pregnancy).	- giving	birth	in	the	Banjul	area	- infants	birthweight	≥2kg	- remaining	in	the	Banjul	area	for	first	90	days	postpartum	- Healthy	infants	over	32	weeks	of	gestation	assessed	by	Ballard	score.		
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Hypothesis	 1:	GBS	 ST-specific	maternal-derived	 antibody	 in	 serum	determines	GBS-
colonisation	in	infants;	
Based	 on	 estimates	 from	 the	 pilot	 study	 of	 100	 women	 in	 The	 Gambia	 which	









better	 ability	 to	 kill	 GBS	 in-vitro	 and	 this	 represents	 a	 laboratory	 surrogate	 for	
protection	from	disease;	




Using	 the	 sample	 size	 of	 150	 colonised	 mothers	 calculated	 for	 hypothesis	 1,	 the	
standard	 error	 and	 95%	 confidence	 intervals	 (CI)	 were	 calculated	 for	 GBS	 ST	







































































































































































	 Total	 Colonised	 Non-colonised	 p-value	 OR	(95%	CI)	
Maternal	Age	yrs.	 <20	 110	 40	 70	 0.78	 1	
	 20-24	 262	 81	 181	 	 0.78	(0.5-1.3)	
Mean:	25	(IQR	18-41)	 25-29	 203	 71	 132	 	 0.94	(0.6-1.5)	
	 30+	 175	 61	 114	 	 0.99	(0.6-1.7)	
	Ethnicity	 Mandinka	 315	 115	 200	 0.38	 1	
	 Wolof	 108	 36	 72	 	 0.9	(0.5-1.4)	
	 Fula	 126	 45	 81	 	 1	(0.6-1.5)	
	 Jola	 118	 33	 85	 	 0.7	(0.4-1.0)	
	 Other	 81	 23	 58	 	 0.7	(0.4-1.2)	
































































Gravida	 1	 208	 67	 141	 0.44	 1	
Median:	2	(IQR	1-4)	 2-4	 370	 121	 249	 	 1	(0.7-1.5)	
	 5+	 169	 63	 116	 	 1.3	(0.8-2.0)	
	 Missing	 3	 1	 2	 	 	
Parity	 0-1	 212	 68	 144	 0.59	 1	










Living	children	 0	 230	 80	 150	 0.17	 1	
Median:	1	(IQR	0-3)	 1-4	 465	 155	 311	 	 0.9	(0.7-1.3)	
	 5+	 53	 17	 36	 	 0.9	(0.5-1.7)	
	 Missing	 2	 2	 0	 	 	
Spontaneous	abortion	 0	 649	 213	 436	 0.09	 1	
Median	1(IQR	0-2)	 1	 53	 20	 33	 	 1.2	(0.7-2.2)	
	 2+	 14	 7	 7	 	 1.5	(0.8-2.7)	
























































Infant	Sex	 Male	 369	 122	 247	 0.59	 1.1	(0.8-1.5)	
	 Female	 381	 131	 250	 	 	
Birth	Weight	(kg)	 2.0-3	 260	 73	 187	 0.04	 1	
	 3.1-4	 464	 169	 295	 	 1.5(1.1-2.0)	
	 >4.0	 26	 						11	 15	 	 1.9	(0.8-4.3)	
Gest.	Age	at	birth	(wks.)	 <34		 56	 18	 38	 0.03	 1	
	 34-37	 231	 83	 148	 	 0.7	(0.4-1.1)	


























































































Attendance	by	midwife	or	TBA	 Midwife	 1	 	















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ia	 7956	(4218-8607)	 4445	(5324-7622)	 2191(1000-3090)	
III	 9348	(7083-9976)	 3784	(2741-4561)	 2301	(1000-3189)	
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Table	12	–	Mean	and	standard	deviation	FI	and	coefficient	of	variance	of	zymosan	
by	month	of	study	and	overall	
	Zymosan	 Jan	 Feb	 Mar	 Apr	 May	 Jun	 Jul	 Aug	 Sep	 Overall	
SD	 8934	 8410	 8482	 8980	 9948	 8890	 8991	 8549	 8293	 8831	
Mean	 28999	 27778	 29776	 28888	 24447	 27602	 29993	 28872	 25559	 27990	















































Bac	Only	 Bac	+	Conj	 Bac	+	Comp	 Bac	+	Conj	+	Comp	
FI
	










































































































































































































		 OPKA	+	 OPKA	-	 		
CDA	+	 True	positive	(A)	 False	positive	(B)	 (A+B)	
CDA	-	 False	negative	(C)	 True	negative	(D)	 (C+D)	




























































































































































































































































































































STIa	 STIb	 STII	 STIII	 STV	




































STIa	 STIb	 STII	 STIII	 STV	
'	




















	 ≥2000	 <2000	 ND	 ≥2000	 <2000	 ND	
Ia	 394	(53)	 93	(12)	
263	
(35)	 238	(38)	 63	(10)	 327	(52)	
Ib	 330	(44)	 112	(15)	
308	
(41)	 220	(35)	 62	(10)	 346	(55)	
II	 415	(55)	 110	(15)	
225	
(30)	 273	(43)	 78	(12)	 277	(44)	
III	 396	(53)	 84	(11)	
270	
(36)	 241	(38)	 67	(11)	 320	(51)	
V	 405	(54)	 120	(16)	
225	























































































Variable	 	 Coefficient	 95%	CI	for	
coefficient	
p-value	
Maternal	factors	 	 	 	 	
Age	 	 0.007	 -0.004	to	
0.019	
0.223	
Weight	(kg)	 	 -0.000	 -0.005	to		
0.004	
0.83	














Infant	factors	 	 	 	 	
Birth	weight	 	 		.1290985	 .0130307				
.2451663	
0.029	
Season	of	birth	 Dry	hot	 .1860007	 .0577072				
.3142943	
0.005	
	 Wet	 .2085752	 .0939361				
.3232143	
<0.001	

















































≥1	 ≥2	 ≥3	 ≥4	 5	
cord	 infant	


































sensitivity	 speci5icity	 PPV	 NPV	overall	 STIa	 STIII	 STV	




















































































































































































































































































































































































































































































































































































































































































































































































GBS	ST	 Log10	FI-C’	 FI-C’	 OPkA	titre	
STIa	 3.01	 1000	 1:100	
STIII	 3.47	 2951	 1:400	









































































Serotype	 Intercept	(95%	CI)	 Slope	(95%	CI)	 P	
Ia	 3.70	(3.64-3.75)	 -0.09	(-0.15	to	-0.03)	 0.0009	
II	 3.75	(3.7-3.79)	 -0.1	(-0.14	to	-0.07)	 <0.0001	
III	 3.69	(3.65-3.74)	 -0.1	(-0.14	to	-0.05)	 <0.0001	



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Professor Beate Kampmann 
Vaccinology Theme Leader 






Dear Professor Kampmann 
 
L2014.08v2, Re SCC 1350v3: Group-B streptococci in pregnant women and 
their infants in the Gambia- A fresh look at prevalence, serotypes and antibody 
is required 
 
Thank you for submitting your response letter dated 6 February 2014 addressing the 
issues raised by the SCC at its meeting held on 3 February 2014.  
 
I am pleased to approve your request which will be forwarded to the Ethics Committee 
for consideration at its meeting on 28 February 2014.  
 




Professor Umberto D’Alessandro 






Additional documents submitted for review:-  
x Consent Form (adult), version 2.0 – 27 January 2014 
x Informed Consent Document (child), version 3.0 – 8 January 2014 
x SCC Application Form: SCC 1350 
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P-0. Box 273, Banjul 
The Gambia, West Africa 
ETHICS COMMITTEE 
Fax: + 2 2 0 - 4 4 9 5 9 1 9 or 4496513 
Tel: +220-4495442-6 Ext 2308 
Email: ethics@mrc.gm 
11 March 2014 
Professor Beate K a m p m a n n 
Vacc ino logy Theme Leader 
MRC Unit, The Gamb i a 
Fajara 
Dear Professor K a m p m a n n 
L2014 .08 , Re SCC 1350v3 : G roup -B s t rep tococc i in p regnan t w om en and the i r 
in fants in the Gam b i a - A f r esh look at p reva l ence , se ro t ypes and an t ibody is 
requ i red 
Thank you for submi t t ing your letters dated 21 January and 6 February 2014 for 
cons iderat ion by the Gamb i a Gove rnmen t /MRC Joint Ethics Commi t t e e at its meet ing 
held on 28 February 2014 . 
We are p leased to approve your request . 
With best w ishes 
Yours s incere ly 
Mr Ma lamin Sonko 
Cha i rman , Gamb i a Gove r nmen t /MRC Joint Ethics Comm i t t ee 
Docum ents subm i t t ed fo r rev iew :-
• Consent Form (adul t ) , vers ion 2.0 - 27 January 2014 
• Informed Consen t Documen t (chi ld) , vers ion 3.0 - 8 January 2014 
• SCC App l i cat ion Fo rm: S C C 1350 
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Mr Malamin Sonko. Chairman 
Professor Ousman Syan. Scientific Advisor 
Ms ^affte Jobe. Secretary 
Mrs Tulai Jawara-Ceesay 
Dr Ahmadou l.amin Samateh 
Dr Roddie Cole 
Prof. Umherto D'Alessandro 
Dr Stephen Howie 
Dr Kalifa Bo Jang 
Dr Ramatoulie Sjie 
Dr Momodou L Waggeh 
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All	 information	that	 is	collected	about	you	and	your	baby	 in	the	course	of	the	study	will	be	kept	
strictly	confidential.	You	and	your	baby’s	personal	 information	will	only	be	available	to	the	study	
team	 members	 and	 might	 be	 seen	 by	 some	 rightful	 persons	 from	 the	 Ethics	 Committee,	
Government	authorities	and	sponsor.	
Who	should	you	contact	if	you	have	questions?	
Please	 feel	 free	 to	 ask	 any	 question	 you	might	 have	 about	 the	 research	 study.	 If	 you	 have	 any	
queries	or	concerns	you	can	contact	Dr	Kirsty	Le	Doare	on	[Phone	number],	and	you	can	always	call	
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I	agree	to	allow	my	child	take	part	in	this	study	 Yes	 	 No	 	
I	agree	to	further	research	on	my	child’s	samples	as	described	in	the	
information	sheet	 Yes	 	 No	 	
Participant/parent/guardian	
signature/thumbprint*	
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obtaining	consent	 	 	 	





Identification code: SOP-CTS-015, adult version 2.0. 27/01/2014  





Participant Identification Number: |__|__|__|__|__|__|__|__|__|__|__|__| 
I,   
 (Printed name of participant) 
 have read the written information OR 
 have had the information explained to me by study personnel in a language that I understand and 
• confirm that my choice to participate is entirely voluntarily, 
• confirm that I have had the opportunity to ask questions about this study and I am satisfied with 
the answers and explanations that have been provided, 
• understand that I grant access to data about me to authorised persons described in the 
information sheet, 
• confirm that I agree to samples taken during this study being taken outside of the Gambia for 
further study 
• have received time to consider to take part in this study.  
Tick as appropriate 
I agree to take part in this study Yes  No  
I agree to have an HIV test Yes  No  
I agree to have a rectovaginal swab taken when I am in labour Yes  No  
I agree to further research on my samples as described in the 




    
   Date (dd/mmm/yyyy) Time (24hr) 
Printed name of witness*  
 
Printed name of person 
obtaining consent 
 
I attest that I have explained the study information accurately in ______________________ to, 
and was understood to the best of my knowledge by, the participant. He/she has freely given 
consent to participate *in the presence of the above named witness (where applicable).  
Signature of person 
obtaining consent    
   Date (dd/mmm/yyyy) Time (24hr) 
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GAMI Study Visit 1 (Birth) – Case report form (CRF) 
 
























 Last First  
 
Study mother medical information 
  
(Tick yes or no) 
 
If no give details: 
Was the HIV rapid test done after delivery? 
(NB. There is no need to document HIV test results 
from during the pregnancy or earlier) 
 Yes I___I No I___I  
 
Please document HIV rapid test result 
Yes I___I No I___  
 
 
 SO (negative): 
 
     I___I  
 S1 (HIV1+ve): 
 
     I___I 
 S2 (HIV2 +ve):      I___I 
 
If HIV rapid test indicates a possible +ve status, if not already done so, take mother’s blood for serology 
testing. Send sample to MRC lab as URGENT. Continue to proceed to complete the study visit activities, and 
review serology result at next visit. 
 
  






Was HIV serology testing done after delivery? 




HIV serology result SO (negative): 
 
     I___I  
 S1 (HIV1+ve): 
 
     I___I 
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Study infant medical information 
 
 
 Feeding history 
 
(Tick yes or no) 
 
If no give details: 
 
Is the infant feeding well? 
 
 
Yes I___I No I___I 
 
 
Please indicate the feeding type: 
 
Exclusive breastfeeds I___I Formula milk I___I  
 
Please specify which formula if known………………………. 
 
Mixed breast and bottle feeds I___I 
 
Expressed breast milk (EBM) by bottle I___I 
 
Supplemental water I___I 
 






 History of infectious episodes 
 
(Tick yes or no) 
 
 
If yes give details: 
 




Yes I___I No I___I 
 
Is the infant jaundiced?  
Yes I___I No I___I 
 
Symptoms or signs of significant illness or infection 




Yes I___I No I___I 
 
Any admission to hospital in the past 1 –week? Yes I___I No I___I  
Any episodes of the folllowing?:   
Malaria Yes I___I No I___I  
Septicaemia Yes I___I No I___I  
Pneumonia Yes I___I No I___I  
Meningitis Yes I___I No I___I  
Worms Yes I___I No I___I  
Diarrhoea Yes I___I No I___I  
Otitis media Yes I___I No I___I  
Tonsilitis Yes I___I No I___I  
Upper respiratory tract infection Yes I___I No I___I  
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I___I___I . I___I 
  






















I___I___I . I___I 
 
If the vital signs are abnormal the infant should be reviewed by the study clinician 
Eligibility assessment for continued enrolment 
 
In order to continue to be eligible for inclusion in the study, the mother and infant must meet the inclusion 
criteria and none of the exclusion criteria. 
 Inclusion criteria 
 
Inclusion criteria met? 




Ability to comply with the study procedures as 











Exclusion criteria met? 




Significant congenital abnormalities?  
 




Mother HIV positive on rapid test AND confirmed on 








Symptoms or signs of significant illness or infection 






Yes I___I No I___I 
 
4. Planning to move from the area within the next 2 months that would mean she cannot attend clinic 













Any other condition or situation meaning that 










Any reason that would prevent the study endpoints 
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Do any of the vital signs or examination findings exclude the 




Yes I___I No I___I 
 
If yes, do not proceed to taking 
nasopharyngeal and rectal swabs. If in 








Name:     
 Last First  
 
Signature:     
 
 




Yes I___I No I___I 
 
If yes, proceed to rectal and 
nasopharyngeal swab taking and obtain a 
breast milk sample from the mother 
 
If no, do not proceed to swab the baby & 
discuss with study clinician 











Yes I___I No I___I 
 
















Standard Operating Procedure 3.  
 
SOP Title: Breast Milk Collection and processing 
SOP Version: 02   
Category: Clinical 
Prepared by: Dr Kirsty Le Doare, WT Clinical Research Fellow 
Signature and date:  
Reviewed by: Dr Ed Clarke, Head of Infant Immunology 
Signature and date:  
Amended from:   
Date effective: 14 November 2013 
 
1. BACKGROUND  
According to GAMI study protocol (dated 14 Jan 2014), 2-5 mls of 
breast milk will be collected from mothers who have given verbal 
consent to participate in the study.  
2. PURPOSE AND SCOPE 
This standard operating procedure (SOP) describes the process of 
collection of breast milk from mothers who have given consent to 
participate in this longitudinal study.   
 
The aim of breast milk collection is to explore the role of antibody 
in protecting newborn infants from colonisation with Group B 
streptococcus. 
 
This SOP applies to the study nurses, government midwives, and 
study ciinicians involved in this procedure.  
3. ABBREVIATIONS  
MRC Medical Research Council; representing MRC Unit 
The Gambia 
SOP Standard Operating Procedure 
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4. RESPONSIBLE PERSONS  
The study team, including the government midwives identify 
pregnant women at the labour ward of Faji Kunda health centre 
who meet the study inclusion criteria. A study information sheet is 
provided and explained. The woman is advised that full written 
consent will be sought by the study team after she has recovered 
suitably from the delivery should she wish to take part.  
5. PROCEDURE 
5.1. Confirm that written consent is given for breast milk sample to be 
taken and stored.  
 
5.2. Explain the procedure to the mother.  
 
5.3. Make available properly labeled breast milk specimen containers as 
follows: 2 x clear universal containers. (These containers are 
available on the labour ward in pre-prepared packs. All containers 
are marked with a black line to indicated the fill level) 
 
5.4. As the mother to wash her hands and provide sterile cotton wool 
and 0.02% chlorhexidine to the mother.  
 
5.5. Show the mother how to clean the nipple area and areola of the 
breast from which milk will be taken.  
 
5.6. Ask the mother to express milk from each breast into separate 
containers.  
 
5.7. Ask her to manually express her milk. Remove the first 0.5ml that 
will be introduced on a tissue and discarded appropriately.  Ask her 
to directly express into the sterile plastic tube (universal container) 
to collect approximately 5mls and place in a cold box.  
 
5.8. Put a sticker on the laboratory form, the corresponding CRF section 
and the tube. 
 
5.9. Complete the field sample log sheet kept at the clinic. 
 
5.10. Ensure that the specimen remains on wet ice in the cold box and is 
transported to the lab within six hours of collection to the 
designated laboratory staff. Complete the appropriate sample log 
book kept at the laboratory. 
 




6. LABORATORY HANDLING 
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6.2 Following receipt of the completed Breast milk sample from the Faji 
Kunda Health Centre team, take the right breast samples and 
centrifuge for 30 mins at 3200 rpm. Remove the fat layer with a 
scalpel and store separately. 
6.3.  Aliqout Whey into 1mL aliquots and label tubes. 
6.4. Freeze at -70 degrees.  
6.5. Record the freezer location in the Sample log book, sign and date 
the record. 
6.6. Take the left breast and dilute 5mL breastmilk in 5mL sterile 
phosphate buffered saline (PBS)  
6.7. Centrifuge at 805g for 20 minutes at 20°C.  
6.8.  Remove the fat layer with a scalpel.  
6.9.  Wash the cell pellet in 5mL PBS and recentrifuge. Then repeat this 
wash step. 
6.10. Resuspend in 7% fetal bovine serum in PBS. 
6.11. Count cells using a hemocytometer. 





SCC 1350 – Feb 2014  
• Study Protocol - Group-B Streptococcal Antibody in Mothers 
and Infants (GAMI) January 2014 
8. ATTACHMENTS 
• Participant Information Sheet and consent form (English), 
version 1.0   
• Breast Milk collection form 
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Standard Operating Procedure 4.  
 
SOP Title: Cord blood Collection 
SOP Version: 01    
Category: Clinical 
Prepared by: Dr Kirsty Le Doare, Clinical Research Fellow 
Signature and date:  
Reviewed by: Dr Ed Clarke, Head of Infant Immunology 
Signature and date:  
Amended from: 
 
SOP by Aderonke Odutola for study protocol SCC 
1173 (Dr Martin Ota, Principal Investigator) 
Date effective: 14 November 2013 
 
1. BACKGROUND  
According to GAMI study protocol (dated 14 Jan 2014), 5 mls of cord 
blood will be collected during delivery from the newborn of mothers who 
have given verbal consent to participate in the study at the Faji Kunda 
Health centre.  
2. PURPOSE AND SCOPE 
This standard operating procedure (SOP) describes the process of 
collection of cord blood from newborns of mothers who have given 
consent to participate in this longitudinal study.   
 
The aim of cord blood collection is to explore the role of antibody in 
protecting newborn infants from colonisation with Group B streptococcus. 
 
This SOP applies to the study nurses, government midwives, and study 
ciinicians involved in this procedure.  
3. ABBREVIATIONS  
MRC Medical Research Council; representing MRC Unit The 
Gambia 
SOP Standard Operating Procedure 
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4. RESPONSIBLE PERSONS  
The study team, including the government midwives identify pregnant 
women at the labour ward of Faji Kunda health centre who meet the 
study inclusion criteria. A study information sheet is provided and 
explained. The woman is advised that full written consent will be sought 
by the study team after she has recovered suitably from the delivery. 
The cord blood sample will be stored safely, but discarded should she 
decide not to partake in the study. 
5. PROCEDURE 
5.1 Confirm that verbal consent is given for cord blood sample to be taken 
and stored.  
 
5.2 Confirm the delivery is a potentially uncomplicated (not high-risk) case. 
 
5.3 Explain to the pregnant woman in labour what you are about to do and 
remind her the reason for collecting the cord blood. 
 
5.4 Make available properly labeled blood sample tubes as follows: 2 x yellow 
top. (These tubes are available on the labour ward in pre-prepared 
packs. All tubes are marked with a black line to indicated the fill level)  
 
5.5 Make available sterile alcohol swabs and a 10ml syringe with a green 
needle. 
 
5.6 Put on a pair of sterile gloves as soon as delivery of the baby is 
imminent. 
 
5.7 Immediately following the delivery of the baby but before the placenta 
separates, identify the large thin-walled opening of umbilical vein lying 
superiorly. 
 
5.8 Remove any used gloves and put on a pair of new gloves. 
 
5.9 Ensure that the cord is lying low between the mother’s legs to avoid back 
flow of blood. 
 
5.10 Clean cord properly with alcohol swab (or gauze soaked in spirit) and 
allow to dry. This is to avoid contamination e.g. with maternal blood. 
 
5.11 Puncture the umbilical vein close to the positioned clamp (this is to 
allow for repositioning of clamp in the event of significant 
bleeding after venepuncture) on the portion of the cord attached to 
the placenta with a sterile/new needle and syringe and withdraw about 




SOP 02, SCC 1350  MRC (UK) The Gambia 
 
 
Version 2.0 – March 2014  Page 3 of 4 
Confidential, unauthorised copying prohibited 
 
 












5.13 If significant bleeding from venepuncture site reposition clamp in front of 
the site or asked attending midwife to if other than you.  
 
5.14 Store blood in the provided cool box.  
 
5.15 Transport the cord blood in a cold box (packed with ice-packs) within 6 
hours of collection to the infant immunology laboratory at MRC, Fajara 
 
5.16 Complete the study cord blood collection form completely leaving no 
blank space.  
 
5.17 Thank the mother and the attending midwife/midwives. 
 
6. LABORATORY PROCESSING 
6.1.  Centrifuge at 1000g for 10 minutes.  
6.2.  Aliquot the separated serum into 1mL aliquots. 
6.2a Correctly label each tube and date. 
6.3. Freeze at -70 degrees C. 
6.4. Record the freezer location in the sample log book, sign and date the 
record. 
7. REFERENCES 
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• Study Protocol - Group-B	 Streptococcal	 Antibody	 in	 Mothers	 and	
Infants	(GAMI)	 January	2014 
8. ATTACHMENTS 
• Participant Information Sheet and consent form (English), version 
1.0   









Standard Operating Procedure 5.  
 
SOP Title: Nasopharyngeal and rectal swab collection 
SOP Version: 01    
Category: Clinical 
Prepared by: Dr Kirsty Le Doare, Clinical Research Fellow 
Signature and date:  
Reviewed by: Dr Ed Clarke, Head of Infant Immunology 
Signature and date:  
Amended from: 
 
SOP by Dr Brenda Kwambana and approved by Dr 
Martin Antonio 
Date effective: 1 March 2014 
 
1. BACKGROUND  
According to GAMI study protocol (dated 14 Jan 2014), nasopharyngeal 
and rectal swabs will be taken from infants during the first 3 months of 
life. It	has	been	 suggested	 that	GBS	 initially	 colonizes	 the	 infant’s	oropharyngeal	
mucosa	when	contact	with	maternal	vaginal	 secretions	occur	at	 the	 time	of	birth	
(1). Group-B Streptococcus is an enteric pathogen and it is thought that 
gut translocation is the primary route for invasive disease in the newborn 
period. Although the specific mechanisms are poorly understood, 
attachment to the nasopharyngeal epithelial surface and gut mucosal 
surface is thought to be an essential step in the development of mucosal 
and invasive disease [2,3]. Hence, sampling of the nasopharynx and 
rectum can provide invaluable insights into the epidemiology and 
mechanisms of pathogenicity of GBS.  
 
Purpose	and	Scope	
This standard operating procedure (SOP) describes the process of 
collection of nasopharyngeal and rectal swabs from infants of mothers 
who have given consent to participate in this longitudinal study.   
2. ABBREVIATIONS  
NPS Nasopharyngeal swab 
RS  Rectal Swab 
SOP Standard Operating Procedure 
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STGG Skim milk-tryptone-glucose-glycerol (STGG) 
transport medium 
3. RESPONSIBLE PERSONS  
The study team, including the government midwives identify pregnant 
women at the antenatal clinic or the labour ward of Faji Kunda health 
centre who meet the study inclusion criteria. A study information sheet is 
provided and explained. The study team seeks full written consent after 
the mother has recovered suitably from the delivery. A NPS and RS 
sample is collected within the first 48 hours of life. Two further NPS and 
RS samples are collected during the first 3 months of life. All operators 
must be qualified nurses or healthcare assistants. 
 
4. FIELD PROCEDURE 
 
4.1. Ensure that a clean environment is attained to avoid contaminating 
the sample. 
 
4.2. Prepare sterile gloves, sterile calcium alginate fiber tip swabs and a 
2 vials containing 1ml of STTG medium in each. 
 
4.3. Check that the subject’s ID is included in the list of NPS and RS 
swabs to be taken 
 
4.4. Check that the ID number on the subjects identity card and subject 
study folder and the ID on the NPS and RS form all coincide. If 
there is any discrepancy between the ID on any of the records then 
the field worker should not proceed with the collection of the 
sample, but consult with the field supervisor/coordinator. 
 
4.5. Explain the procedure to the mother 
 
4.6. Use only calcium alginate fiber tip swab 
 




4.8. Position the infant in a supine position (on their back), with the 
infant’s head furthest away from you, and the infant’s legs pointing 
towards you. If a firm flat surface cannot be sought, this can be 
done on the knees of the nurse carrying out the procedure (as 
shown in the figure below). The infant should be briefly swaddled 
for the short period of the procedure. This will allow the infant to be 
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Figure 1. Collection of NPS from an infant 
 
 
4.9. Measure the distance which the swab should be passed, which is 
about half the distance from the nostril to the ear lobe. 
 
4.10. Tip the infant’s head slightly backward and pass the swab directly 
backwards, parallel to the floor of the nasopharynx. The swab 
should pass without resistance until it reaches the posterior 
pharynx. 
 
4.11. If resistance is encountered, remove the swab and pass through 
the other nostril. 
 
4.12. Once the swab is in place, leave in position for five seconds to 




Figure 2. Passage of a sterile swab through the nasal cavity to 
the nasopharynx 
 
4.13. Place the tip in a vial containing 1ml of STGG transport media. 
Using a pair of scissors wiped with alcohol, cut off the excess wire 
handle, leaving the tip in the transport media. Then tighten the cap 
and label the vial and place on wet ice.  
 
4.14. Dispose what remains of the wire loop into “sharps” box 
 
4.15. Remove any used gloves and dispose of into a yellow clinical waste 
bag. 
 
4.16. Keep a record of the presence or absence of nasal mucous and 
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4.17. Ensure that the specimen is placed in the cool box provided 
(containing 2 ice packs) and is transported to the lab within six 




4.18. Position the infant in a supine position (on their back), with the 
infant’s head furthest away from you, and the infant’s legs pointing 
towards you. If a firm flat surface cannot be sought, this can be 
done on the knees of the nurse carrying out the procedure. The 
infant should be briefly swaddled for the short period of the 




4.19. Hold the infant’s legs up and pass the swab directly backward so 
that the tip is just inside the rectum (about 0.5cm). The swab 
should pass without resistance. 
 
4.20. If resistance is encountered, remove the swab immediately. 
 
4.21. Once the swab is in place, leave in position for five seconds to 




Figure 2. Passage of a sterile swab to the rectum 
 
4.22. Place the tip in a vial containing 1ml of STGG transport media. 
Using a pair of scissors wiped with alcohol, cut off the excess wire 
handle, leaving the tip in the transport media. Then tighten the cap 
and label the vial and place on wet ice.  
 
4.23. Dispose what remains of the wire loop into “sharps” box 
 
4.24. Remove any used gloves and dispose of into a yellow clinical waste 
bag. 
 
4.25. Keep a record of the presence or absence of faeces/meconium and 
whether or not the procedure was adequately carried out.  
 
4.26. Ensure that the specimen is placed in the cool box provided 
(containing 2 ice packs) and is transported to the lab within 90 
minutes of collection  
 
 
4.27. Report any problems such as bleeding or excessive pain (crying in 
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5. LABORATORY PROCEDURES (AT THE MRC FAJARA) 
5.1. Prepare STGG transport medium as below: 
 
Oxoid tryptone soya broth  3.0g  
Glucose    0.5g  
Oxoid skim milk powder  2.0g  
Glycerol    10.0g(1.25g=1ml)  
Double distilled water   100.0 ml  
 
5.2 Dispense in 1.0 ml amount in Nunc or Nalgene cryotubes and 
autoclave for 10minutes at 121°C.  
 
5.3 Tighten the lids before storage.  
 
5.4 Store at 4-8°C or room temperature.  
 
5.5 NB/ Prior to use vortex to re-suspend the pellet for a minimum of 
10-15 seconds.  
 
5.6 Transfer to Faji Kunda Health Centre team in cool box with 2 ice 
packs for NPS and RS to be taking according to field procedure. 
 
5.7 Following receipt of the completed NPS and RS sample from the 
Faji Kunda Health Centre team, vortex the specimen for 10-20 
seconds. Aliquot 0.5mL of STGG into a separate cryotube. Correctly 
label and date each samples and store in –70°C freezer.  
 
5.8 Record the freezer location on the Sample Collection form and sign 
and date the record. 
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6. APPENDIX 1. 
Quality control of STGG medium  
 
Appearance: 
- The solution should be tan in colour with a precipitate at the bottom 
of the tube. 
 
Sterility: 
- Select at random 1 vial from each batch. Vortex until the precipitate 
is suspended and plate 100 µL each on Sheep Blood agar. Incubate 
overnight at 37 °C in 5% CO2 and examine the plate for any growth. 
There should be no growth whatsoever. If there is any growth, 
discard the batch and prepare fresh medium.  
 
Performance: 
- Vortex a vial to suspend the precipitate and inoculate it with a 
representative vaccine strain of pneumococcus. Freeze at -70°Cfor 48 
hours. Thaw out specimen at room temperature, vortex again, 
subculture 100 µL onto GBA plate and streak. Incubate overnight at 
37°C in 5% CO2. The organism should show good growth.  
 
7. ATTACHMENTS 
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According	 to	GAMI	 study	 protocol	 (dated	 14	 Jan	 2014),	 rectovaginal	 swabs	will	 be	 taken	
from	women	 in	 labour.	Group-B	Streptococcus	 is	an	enteric	pathogen	and	colonization	 in	













The	 study	 team,	 including	 the	 government	 midwives	 identify	 pregnant	 women	 at	 the	
antenatal	 clinic	 or	 the	 labour	 ward	 of	 Faji	 Kunda	 health	 centre	 who	 meet	 the	 study	
inclusion	 criteria.	 A	 study	 information	 sheet	 is	 provided	 and	 explained.	 The	 study	 team	
seeks	 full	written	 consent	 after	 the	mother	 has	 recovered	 suitably	 from	 the	 delivery.	 An	
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Glucose	 	 	 	 0.5g		
Oxoid	skim	milk	powder		 2.0g		
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- Nutrient	broth	 	 84ml		
- Glycerol	 	 	 16ml		
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Summary Objectives: To determine risk factors for GBS colonisation in Gambian mothers
and in their infants from birth to day 60e89 of age.
Methods: Swabs and breastmilk from mothers/infant pairs were collected and cultured on se-
lective agar. Negative samples were analysed for GBS DNA via real-time PCR. Positive isolates
were serotyped using multiplex PCR and gel-agarose electrophoresis.
Results: Seven hundred and fifty women/infant pairs were recruited. 253 women (33.7%) were
GBS-colonised at delivery. The predominant serotypes were: V (55%), II (16%), III (10%), Ia
(8%) and Ib (8%). 186 infants were colonised (24.8%) at birth, 181 (24.1%) at 6 days and 96 at
day 60e89 (14%). Infants born before 34 weeks of gestation and to women with rectovaginal
and breastmilk colonisation at delivery had increased odds of GBS colonisation at birth. Season
of birth was associated with increased odds of persistent infant GBS colonisation (dry season
vs. wet season AOR 2.9; 95% CI 1.6e5.2).
Conclusion: GBS colonisation is common in Gambian women at delivery and in their in-
fants to day 60!89 and is dominated by serotype V. In addition to maternal
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colonisation, breastmilk and season of birth are important risk factors for infant GBS
colonisation.
Crown Copyright ª 2015 Published by Elsevier Ltd on behalf of The British Infection
Association. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Introduction
Group B Streptococcus (GBS) is a leading cause of neonatal
infection worldwide and transmission occurs mainly from
mother to child during the peripartum period.1 In the Afri-
can setting, information on GBS disease prevalence remains
sparse.2 Under-identification and under-reporting of GBS
cases and deaths appear likely, especially where it is diffi-
cult to access healthcare. Maternal colonisation is the lead-
ing risk factor for both early and late onset GBS disease,1
yet in resource-poor countries little is known about
maternal colonisation rates. Little is also known about
maternal or infant colonising serotypes in African countries
but reports indicate that serotype (ST) V may be important
as both a colonising and invasive disease serotype,3,4 as it
was in the USA in the 1990s.5
The current leading candidate for maternal vaccination
is a trivalent capsular polysaccharide protein conjugate
vaccine containing ST Ia, Ib and III which is based on data on
invasive disease serotypes in the USA, UK6 and South Af-
rica.3 Here, we report the results of a longitudinal prospec-
tive cohort study to investigate the prevalence of colonising
and invasive disease serotypes of Gambian women and their
infants from delivery to three months of age.
Methods
Study design and participants
We undertook a prospective longitudinal cohort study in
two government health centres offering antenatal care to
women in the Fajara area of costal Gambia, a low-income
country with an annual birth rate of 43.1/1000 population,
neonatal sepsis rate of 4.42/1000 live births7 and neonatal
mortality rate of 28/1000 live births.8 The combined birth
rate of these two health centres is approximately 12,500
births annually. The health centres were selected to be
representative of the level of care usually available to
Gambian women.
The eligibility criteria for maternal participation in the
study included all pregnant women over the age of 18 years
who had a negative HIV test and were deemed to be at low
risk for pregnancy complications (no evidence of pre-
eclampsia, cardiomyopathy, maternal gestational diabetes,
placenta praevia, twin pregnancy). Women were invited to
deliver at the health centre and offered a confirmatory HIV
test prior to enrolment. Women found to be HIV positive
were referred for specialist ongoing care. Mothers were
excluded if they were not planning to breastfeed or were
unable to remain in the Fajara area for the first three
months postpartum. Healthy infants over 32 weeks of
gestation assessed using the Ballard score and weighing
over 2.5 kg were included. Infants were excluded if they
had obvious congenital abnormalities or required resusci-
tation at the time of delivery requiring transfer to a
neonatal unit. Mother and infant pairs were recruited to
the study between 1st January 2014 and 31st December
2014 if both mother and infant met the inclusion criteria.
All eligible women and infants were recruited until the pre-
defined sample size was reached. Participants were fol-
lowed up daily at home until day 6 and then asked to return
to clinic when the infant 60!89 days old for final follow up
visit and vaccinations. If an infant died during the study a
verbal autopsy was carried out to assess the potential cause
of death.
Ethics statement
Field workers explained the purpose of the study to eligible
participants in their local language (Mandinka, Wolof, Fula,
Jolla, Mangago) and each participant signed an informed
consent form, or in case of illiteracy, thumb-printed and
the consent form was signed by an impartial witness. The
study was approved by the joint Gambian Government/




Rectovaginal swabs were taken from enrolled women
presenting in labour to one of the health centres and cord
blood was taken after delivery but prior to separation of
the placenta. A screening questionnaire was completed
after four hours postpartum and the infant checked for any
abnormalities requiring medical intervention. The ques-
tions included ethnic origin, gravida, parity, maternal
weight, blood pressure, haemoglobin concentration, use
of medication/traditional medicines/antibiotics and vacci-
nation in pregnancy, any illnesses in pregnancy, number of
antenatal attendances, HIV status, education, diet, com-
pound location and presence of cattle at the compound.
Nasopharyngeal and rectal swabs were taken from all
eligible infants at four hours after birth. Mothers were
provided with soap and asked to wash their hands and wipe
their breasts with alcohol wipes before hand expressing
colostrum/milk within the first 12 h after birth, at day 6 and
between days 60 and 89. Nasopharyngeal and rectal swabs
were also taken from infants at day 6 of life and again at
60e89 days of life. Infants who were unwell before day 6
were assessed at home and referred for treatment as
necessary. All sick infants had a blood culture taken on
admission to hospital. At each visit a standardized ques-
tionnaire was completed in the local language documenting
infant anthropometry, feeding, vaccinations, signs and
symptoms of infant illnesses, use of antibiotic/traditional
medicine and vital signs.
2 K. Le Doare et al.
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Copan (for rectal and rectovaginal samples) and Dacron (for
nasopharyngeal samples) swabs were collected in skim-milk
tryptone glucose glycerol (STGG) transport medium, stored
at 4 !C and transported to the Medical Research Council
laboratories, The Gambia within 4 h of collection. On
arrival the samples were vortexed briefly and immediately
frozen at "70 !C until processing.
All swab specimens were inoculated into ToddeHewitt
broth supplemented with colistin and nalidixic acid and
were processed for isolation of GBS using standard labora-
tory procedures.1 Presumptive positive GBS samples were
identified by latex agglutination (Oxoid). Five colonies
from positive samples were harvested into phosphate buff-
ered saline (PBS) and subjected to real-time polymerase
chain reaction (PCR).9 Negative samples were also sub-
jected to confirmation by real-time PCR. All GBS positive
isolates were then serotyped using conventional PCR and
identified using gel PCR and agarose electrophoresis.10
Outcomes
The primary outcome was prevalence of ST-specific GBS
colonisation in mothers and infants at birth, six days and
between days 60e89 using microbiological culture and
molecular techniques. Secondary outcomes were detection
of GBS in breastmilk; infant acquisition and loss of GBS
colonisation during the study follow up period and infant
GBS disease (sample obtained from sterile site), as ascer-
tained by positive microbiological culture and confirmatory
PCR. Swabs were considered negative if no GBS was evident
by culture and PCR and positive if GBS was found on culture
and PCR. If swabs were negative on culture but positive on
PCR, conventional PCR was performed to determine sero-
type. If the second PCR resulted in the identification of a
GBS serotype the samples were deemed positive. If no
serotype was identified or the DNA did not amplify, samples
were deemed negative.
Statistical analysis
Calculated on the basis of the previously observed 24%
colonisation rate,11 the intended sample size was 750
mothers, to provide at least 180 colonised women for sero-
type analysis (95% confidence interval (CI) 150e202 women)
and 90 colonised infants (95% CI 72e107 infants). The sam-
ple size of 180 colonised women was chosen to ensure at
least 10 samples of the least prevalent ST based on histor-
ical data from The Gambia (ST III (6%)),11 in order to allow
longitudinal colonisation analysis.
Statistical analyses were completed using STATA version
12 (StataCorp 2013, Texas) and GraphPad Prism version 6.0
(GraphPad Software Inc, La Jolla, California). Descriptive
statistics included the prevalence of colonisation at indi-
vidual time points expressed as a proportion of the total
number of participants. Odds ratios and 95% confidence
intervals (CI) were calculated to determine risk of maternal
and infant colonisation at birth in a single variable analysis.
Adjusted odds ratios were then calculated using any vari-
ables from the single variable analysis with a p-value <0.2
using a backwards-stepwise procedure.
Analyses of the changes in infant colonisation over time
were undertaken using longitudinal logistical regression.
Adjusted odds ratios were then calculated using any
variables from the single variable analysis with a p-value
<0.2 using a backwards-stepwise procedure. New acquisi-
tion of GBS was defined as detection of a new serotype by
culture or PCR that was not previously present. Clearance
of colonisation was defined as a negative GBS culture or
PCR for a specific serotype following a positive sample at
the previous visit for the same ST. The log-rank test was
used to examine differences in duration of colonisation
between serotypes. Using an expected vertical transmission
rate of 50%1 we calculated observed vs. expected statistics
for risk of infant colonisation by ST. For comparison be-
tween our study and the study conducted in 1994, we calcu-
lated 95% confidence intervals for both studies. P-values
<0.05 were considered significant.
Role of the funding source
The funders had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
All authors had full access to all the data and the
corresponding author had final responsibility for the deci-
sion to submit for publication.
Results
Demographics
Between 15th January 2014 and 31st January 2015 we
recruited a total of 750 mothers and their infants to the
study. All mothers met the inclusion criteria except one,
who was admitted to hospital on day three post-partum
severely unwell and subsequently tested positive for HIV1,
despite a negative test at 20 weeks of gestation. She and
her infant were referred for further management and
samples excluded from further analysis. Of the remaining
eligible women and infants, 722 completed the day 6 visit
(median age at follow up 8 days, IQR 7e9) and 684
completed 60e89 days follow up (median age at follow up
62 days, IQR 60e63). The main reasons for not completing
follow up were: 31 women moved out of area, 20 women
whose partners were not in agreement with continued
study participation, one maternal HIV, nine infant deaths,
five declined for other reasons. Participant flow diagram
and demographic characteristics of mothereinfant pairs
are outlined in Supplementary Fig. 1.
Antibiotic treatment
Over the course of the study, 77 women received antimicro-
bials during pregnancy: 34 for urinary tract infection; 10 for
pneumonia; 14 for vaginal discharge; 9 for malaria and 10 for
non-malarial fever. Of these, 73 women received amoxicillin
(median time prior to delivery 42 days [IQR 18e63 days]); 16
received antimalarial therapy (median 38 [31e41]) and three
received erythromycin. In the three months of follow up, 51
infants required antibiotic therapy: 34 received ampicillin
and gentamicin for presumed neonatal sepsis (median 18
days old [IQR 4e34]); 10 received amoxicillin or cloxacillin
for skin infections (20 days [10e58]); 7 received other
antibiotics (18 days [11e23]). Antibiotic therapy was
included in adjusted analyses and had no impact on
colonisation of mother or infant at any time point.
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Table 1 Mother and infant demographics and odds ratios for maternal GBS colonisation at delivery.
Total Colonised Non-colonised p-value OR (95% CI)
Maternal
age yrs
<20 110 40 70 0.78 1
20e24 262 81 181 0.78 (0.5e1.3)
Mean: 25
(IQR 18e41)
25e29 203 71 132 0.94 (0.6e1.5)
30þ 175 61 114 0.99 (0.6e1.7)
Ethnicity Mandinka 315 115 200 0.38 1
Wolof 108 36 72 0.9 (0.5e1.4)
Fula 126 45 81 1 (0.6e1.5)
Jola 118 33 85 0.7 (0.4e1.0)
Other 81 23 58 0.7 (0.4e1.2)
Missing 2 1 1
Maternal
weight (kg)
<50 27 7 20 0.03* 1
50e70 424 128 296 1.2 (0.5e3.0)
70e90 148 61 87 2.0 (0.8e5.0)
>90 145 56 91 1.8 (0.7e4.4)
Missing 6 3 3
Maternal illness
in pregnancy
Yes 128 45 83 0.32 1
No 504 165 339 1.1 (0.7e1.7)
Missing 118 43 75
Maternal Hb below
10 g/dL
No 99 42 57 0.04* 1
Yes 651 211 440 0.5 (0.3e0.9)
Maternal antibiotics
in pregnancy
No 505 166 339 0.74 1
Yes 128 44 84 1.1 (0.7e1.6)
Missing 117 74 43
Gravida 1 208 67 141 0.44 1
Median: 2 (IQR 1e4) 2e4 370 121 249 1 (0.7e1.5)
5þ 169 63 116 1.3 (0.8e2.0)
Missing 3 1 2
Parity 0e1 212 68 144 0.59 1
Median: 1 (IQR 0e4) 2e4 468 164 304 1.1 (0.8e1.6)
5þ 67 20 47 1.1 (0.7e1.7)
Missing 3 1 2
Living children 0 230 80 150 0.17 1
Median: 1 (IQR 0e3) 1e4 465 155 311 0.9 (0.7e1.3)
5þ 53 17 36 0.9 (0.5e1.7)
Missing 2 2 0
Spontaneous abortion 0 649 213 436 0.09 1
Median 1(IQR 0e2) 1 53 20 33 1.2 (0.7e2.2)
2þ 14 7 7 1.5 (0.8e2.7)
Missing 34 16 18
Stillbirths 0 641 207 434 0.05** 1
1 75 29 46 0.9 (0.4e2.1)
2þ 28 15 13 3.6 (1.2e10.5)
Missing 6 2 4
Number of ANC visits 1 303 85 218 0.01* 1
2þ 447 168 279 1.5 (1.1e2.1)
Attendance by midwife
or TBA
Midwife 436 168 268 0.001* 1
TBA 254 67 187 0.5 (0.4e0.8)
Missing 60 37 23
Birth season Dry cool 280 55 225 0.000* 1
Dry hot 175 85 90 3.9 (2.5e5.9)
Wet 295 113 18 2.5 (1.7e3.7)
Infant sex Male 369 122 247 0.59 1.1 (0.8e1.5)
Female 381 131 250
Birth
weight (kg)
2.5e3 260 73 187 0.04* 1
3.1e4 464 169 295 1.5 (1.1e2.0)
>4.0 26 11 15 1.9 (0.8e4.3)
4 K. Le Doare et al.
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Prevalence and risk factors for maternal
colonisation
The overall prevalence of recto-vaginal GBS colonisation at
delivery was 33.7% (253 women). In single variable analysis
maternal weight >50 kg, maternal haemoglobin <10 g/dL,
more than one previous stillbirth, more than one antenatal
clinic visit, midwife delivery, giving birth during the dry hot
or wet seasons, birth weight over 3 kg and gestation under
34 weeks were associated with increased risk of GBS
colonisation (Table 1). In adjusted analysis, maternal hae-
moglobin <10 g/dL, history of more than one previous still-
birth, attendance at delivery by a midwife rather than a
trained birth attendant and giving birth during the wet or
dry hot season were associated with increased odds of
maternal GBS colonisation at delivery (Table 2).
GBS colonisation dynamics at birth
There were 253 colonised mothers and 186 colonised
infants at birth, of whom 146 were born to colonised
women (57.7%). Table 3 describes the number of colonised
infants at birth, day 6 and at 60!89 days of age according
to colonisation site. Fig. 1a and b demonstrate colonisation
dynamics at each time point.
Compared to mother/infant pairs who were not colon-
ised at birth, mother/infant pairs were more likely to both
be colonised if mother’s weight was below 50 kg, infant was
born at less than 37 weeks of gestation, born during the dry
hot or wet seasons, mothers with more than one previous
stillbirth, mothers attending antenatal clinic more than
once, infants delivered by midwives, infants born with a
birth weight below 3.3 kg or receiving breastmilk colonised
with GBS (Table 4).
In adjusted analysis, compared to mother/infant pairs
who were not colonised at birth, mother/infant pairs were
more likely to both be colonised if birth occurred in the dry
hot or wet seasons, mothers with one or more previous
stillbirths or spontaneous abortions, infants born before 34
weeks of gestation. Compared to mother/infant pairs
where neither was colonised, mother/infant pairs where
the mother was colonised but not the infant were more
likely if the mother had more than one previous stillbirth,
or if the mother gave birth during the wet season. Infant
colonisation in the absence of maternal colonisation
(n Z 40) was associated with gestation before 34
weeks (Table 5).
Most notably, compared to mother/infant pairs at birth
where neither were colonised, infants born to mothers who
had GBS cultured in their breastmilk were more likely to be
colonised with GBS (Table 5).
GBS colonisation dynamics at birth, day 6e9 and
day 60e89
Infants born to colonised mothers had an increased risk of
colonisation at birth and day 6e9 if born during the dry hot
season or if born before 34 weeks of gestation. For all
variables the risk of colonisation decreased over time
(Table 6).
Infants born to non-colonised mothers had an increased
risk of being GBS colonised on day 6e9 and at day 60e89 if
born during the wet season. At birth infants were more
likely to be colonised if breastmilk was colonised and they
remained more likely to be colonised at both 6e9 days and
day 60e89.
Serotype distribution
The predominant maternal rectovaginal colonising serotype
was ST V in 54.9% of colonised mothers. Mothers’ breastmilk
was more likely to be colonised with ST V (p < 0.001) at all
time points than any other serotype. Infants were more
likely to be colonised with ST V at birth (p Z 0.004), day
6e9 (pZ 0.004) and day 60e89 (pZ 0.009) than any other
serotypes. At birth, infants were more likely to be colonised
with ST III and V if their mothers were colonised with ST III
and V (x2 Z 24.4, p < 0.001) compared to mothers colon-
ised with other serotypes. Fig. 2 outlines the percentage




<34 56 18 38 0.03* 1
34e37 231 83 148 0.7 (0.4e1.1)
38þ 463 152 311 1.1 (0.7e1.7)
IQR Z inter-quartile range; ANC Z antenatal clinic; TBA Z trained birth attendant. * p-values <0.05 were considered significant.
** p-value Z 0.0475.
Table 2 Multivariable analysis: maternal GBS colonisation
at time of delivery.




50e70 1.0 (0.4e1.6) 0.96
70e90 1.7 (0.6e4.5) 0.30












TBA 0.6 (0.4e0.9) 0.03*
Previous stillbirths 0 1
1 0.9 (0.4e2.0) 0.86
2þ 5.4 (1.6e18.0) 0.009*
Birth season Dry cool 1
Dry hot 2.0 (1.3e3.1) 0.004*
Wet 1.8 (1.2e2.7) 0.008*
ANC Z antenatal clinic, Hb Z haemoglobin; TBA Z trained
birth attendant. * p-values <0.05 were considered significant.
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During the study period, 51 infants (6.8%) presented with
signs of infection (68 per 1000 live births): 18 with signs of
pneumonia, 22 with signs of other febrile illness, ten with
skin infections and one with signs of meningitis. One child
presenting on day 6 of life with irritability and poor
feeding, had a positive CSF culture for GBS and was treated
for 21 days with ampicillin and gentamicin (invasive GBS
disease incidence: 1.3 per 1000 live births). This infant was
born to a mother who had ST V cultured from both
rectovaginal swab and breastmilk at birth and day 6 of
life and the infant swab was also positive at birth and day 6
for ST V. The CSF sample was not typed due to laboratory
constraints.
Nine infants died during the study period. Based on
verbal autopsy, six deaths were due to pneumonia (median
age at death 7 days [IQR 2e35]); three due to sepsis
(median age 6 days [1e48]). Blood cultures were negative
in all cases. One infant was born to a colonised mother and
was also colonised with GBS at the time of birth but was not
colonised on day 6. This infant died of presumed sepsis on
day 48 of life. No other infants who died or their mothers
were colonised with GBS at time of birth or day 6 of life. All
infants died prior to the final follow-up appointment. It is
therefore, not possible to determine whether any of these
deaths were due to GBS disease.
Discussion
In this first colonisation study of Gambian mothers and their
infants for 25 years and the first longitudinal study under-
taken in this population, we demonstrate high prevalence
of GBS colonisation in mothers at birth and in their infants
up to 90 days of life. In addition, we demonstrate that
infants were more likely to be colonised if GBS was isolated
from their mother’s breastmilk. The overall prevalence of
maternal GBS in our population is higher than in the original
Table 3 Dynamics of colonisation by site and time point.
Birth n Z 750; 253 colonised mothers (% total)
Mother and infant colonised 146 (19.5% total; 57.7% born to colonised mothers)
Infants colonised, mothers not colonised 40 (5.3)
Total colonised infants 186 (24.8)
Mothers colonised, infants not colonised 107 (14.3)
Neither mother nor infant colonised 457 (60.9)
Site of colonisation at birth (% colonised infants)
Nasopharyngeal and rectal 96 (51.6)
Rectal only 68. (36.6)
Nasopharyngeal only 22 (11.8)
Site of colonisation day 6e9; n Z 722 (% of the 181 colonised infants)
Infant rectal colonisation only 95 (52.5)
Infant nasopharyngeal colonisation only 29 (16.0)
Infant nasopharyngeal and rectal 57 (31.5)
Site of colonisation day 60e89; n Z 684 (% the 94 colonised infants)
Infant rectal colonisation only 57 (60.6)
Infant nasopharyngeal colonisation only 26 (27.7)
Infant nasopharyngeal and rectal 11 (11.7)
Figure 1 a e infant GBS colonisation status over time. Bars
represent percentage of infants colonised at each of the time
p o i n t s ; b l a c k b a r Z b i r t h , g r e y Z d a y 6 a n d
patterned Z three months. b e breastmilk colonisation over
time. Bars represent percentage of infants colonised at each
of the time points; black bar Z birth, grey Z day 6 and
patterned Z three months.
6 K. Le Doare et al.
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study by Suara et al. (1992) (Suara 22% colonised (95% CI
15.04e28.96) vs. present study 33.7% colonised
(29.63e36.37); p Z 0.007).11 However, the previous study
likely under-identified GBS colonisation as selective me-
dium was not used. An additional feature that may account
for a lower colonisation rate was the collection of vaginal
but not rectal swabs, which are known to have a higher
yield for GBS.12 The prevalence of GBS colonisation in our
study is similar to the reported pooled prevalence in South
African women (30.4%).3
Our finding that mothers with more than one stillbirth
demonstrated an increased odds of having a colonised
infant are in concordance with Monari et al., who identified
stillbirth as a risk factor for invasive EOGBS disease.13 This
phenomenon has also been noted in non-human primates,14
but there are currently little human data on the association
between stillbirth, GBS colonisation and invasive disease.
Table 4 Characteristics of mother infant pairs according
to colonisation status at birth.




<20 110 23 17 2 68
20e24 262 43 38 19 162
25e29 203 46 25 11 121
30þ 175 34 27 8 106
Ethnicity 0.10
Mandinka 315 63 52 23 177
Wolof 108 23 13 8 64
Fula 126 28 17 2 79
Jola 118 21 12 3 82
Other 81 11 12 4 54




<50 27 2 5 4 16
50e70 424 74 54 21 275
70e90 148 36 25 3 84
90þ 145 32 23 9 81
Missing 6 3 0 3 0
Mother ill 0.48
Yes 128 24 21 3 80
No 504 97 68 25 314




No 99 24 18 2 55





No 505 99 92 0 314 0.91
Yes 128 23 24 0 81
Gravida 0.44
1 208 39 28 13 128
2e4 370 67 54 17 232
5þ 169 39 25 10 95
Missing 3 1 0 0 2
Parity 0.94
0e1 212 39 29 13 131
2e4 468 96 68 24 280
5þ 67 10 10 3 44




0 230 43 37 14 136
1e4 465 94 61 25 285
5þ 53 7 9 1 36




0 649 121 92 31 405
1 53 14 6 4 29
2þ 14 7 1 0 6
Missing 34 11 0 5 18
Table 4 (continued )
Total MþIþ MþI" M"Iþ M"I" p-value
Stillbirths 0.03*
0 641 119 87 32 403
1 75 20 9 6 40
2þ 28 5 10 2 11




1 303 58 27 15 203
2þ 447 88 80 25 254
Midwife
delivery
436 108 60 20 248 <0.001*
TBA 254 29 38 12 175
Missing 60 9 9 8 34
Infant sex 0.71
Male 369 72 50 23 224
Female 381 74 57 17 233
Season <0.001*
Dry cool 280 22 33 17 208
Dry hot 175 66 19 3 87




2.5e3 260 44 29 20 167
3.1e4 464 95 74 18 277




<34 56 13 5 4 34
34e37 231 57 26 12 136




Yes 64 31 18 7 8
No 600 101 77 31 391
Missing 86 14 12 2 58
MþIþ Z mother and infant colonised; MþI" Z mother colon-
ised, infant not colonised; M"Iþ Z mother not colonised, in-
fant colonised, M"I" Z neither mother nor infant colonised;
TBA Z trained birth attendant; ANC Z antenatal clinic.
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This finding could be important in reducing adverse preg-
nancy outcomes especially following introduction of any
new vaccine.
The prevalence of infant colonisation in our study is
similar to previous studies in Europe15e18 but higher than
those from other most African countries,19 probably due
to the differences in microbiological methods. To our
knowledge this is the first longitudinal study of infant colo-
nisation and demonstrates that GBS colonisation rates
remain high up to three months of life. We demonstrate
that the overwhelming risk factor for infant colonisation
at all time points was having a mother who was GBS colon-
ised at the time of birth. We also established that delivery
before 34 weeks of gestation increased the odds of GBS
colonisation at birth. Similar studies have indicated that
risk factors for infant colonisation include maternal recto-
vaginal colonisation, preterm delivery, low birth weight
and maternal urinary tract infection.1,15,18,20 However, un-
like these studies we did not identify low birth weight as a
risk factor, probably because we only recruited infants
weighing more than 2.5 kg.
Several case reports suggest that isolation of GBS in
breastmilk is implicated in late onset GBS disease.21,22 Our
data suggest that GBS colonisation in breastmilk is a risk
factor for neonatal colonisation, both at delivery and for
persistence of infant colonisation throughout the first three
months of life. This is an important finding in a population
such as this with high rates of breast-feeding. The mecha-
nism for this is not clear; it is possible that GBS enters
the mammary glands following suckling from a colonised in-
fant, although there is also evidence that normal gut micro-
biota may pass into the breast via the entero-mammary
circulation.23 Whether it is also a risk factor for late onset
disease in this population is not known. Conversely, it might
conceivably be a protective factor through induction of im-
munity.24 The relevance of this finding requires further
study.
It is interesting to note that risk factors for maternal
colonisation include midwife delivery and increasing number
of antenatal visits. This phenomenon has not been previ-
ously noted in resource-poor settings where hygienic birth
practices may be compromised. GBS has been implicated in
nosocomial outbreaks in several hospitals globally,25,26
although the number of reported outbreaks in resource-
rich countries has greatly reduced since the implementation
of GBS screening programmes. It is conceivable that unclean
birth practices, especially in times of clean water shortage,
such as the dry hot season or during the wet season may








Dry cool 1 1 1
Dry hot 8.3 (3.9e17.6) 1.8 (0.8e3.9) 0.4 (0.1e1.4)
Wet 3.5 (1.8e6.8) 2.3 (1.3e4.3) 1.1 (0.5e2.5)
Breastmilk colonised
Yes 21.0 (8.6e51.3) 11.5 (4.5e29.4) 7.5 (2.0e27.5)
No 1 1 1
Gestation (weeks)
<34 1 1 1
34e37 0.9 (0.9e1.0) 1.0 (0.9e1.1) 0.9 (0.8e1.0)
38þ 0.4 (0.2e1.0) 0.5 (0.3e1.6) 0.9 (0.8e1.0)
Midwife delivery 1 1 1
TBA 0.9 (0.5e1.6) 1.0 (0.6e1.8) 0.6 (0.2e1.3)
Number of antenatal clinic visits
1 1 1 1
2þ 1.1 (0.7e1.9) 1.2 (0.8e2.1) 1.3 (0.6e2.8)
Stillbirths
0 1 1 1
1 2.5 (1.0e8.7) 2.0 (1.0e4.7) 1.4 (0.3e5.9)
2þ 2.4 (0.9e4.1) 2.2 (0.9e2.1) ND
Spontaneous abortion
0 1 1 1
1 0.9 (0.5e1.4) 0.8 (0.3e2.1) 1.0 (0.2e5.5)
2þ 1.2 (1.1e2.3) 0.3 (0.0e2.2) 2.0 ND
Gravida
1 1 1 1
2e4 1.0 (0.9e1.0) 1.1 (0.6e2.0) 1.0 (0.8e1.2)
5þ 1.0 (0.5e2.0) 0.8 (0.4e1.8) 0.8 (0.3e2.3)
MþIþZ mother and infant colonised; MþI"Z mother colonised, infant not colonised; M"IþZ mother not colonised, infant colonised,
M"I" Z neither mother nor infant colonised. 1 Z adjusted odds ratios are compared to this group; TBA Z trained birth attendant.
a M"I" Z base group.
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facilitate the fecal-oral spread of GBS between colonised
and non-colonised mothers and their infants.
A large proportion of women were colonised with ST V,
similar to the previous smaller study by Suara et al., which
identified 32 colonised pregnant women of whom 12 (30%)
were colonised with ST V.11 ST V has been identified as an
important neonatal and adult colonising and disease
causing serotype globally.3,27,28 Additionally, in our cohort,
ST V was the predominant serotype cultured in breastmilk
and ST Ib and V were associated with longer median coloni-
sation duration compared to other serotypes. A study of
pregnant women from South Africa found a high prevalence
of GBS colonisation throughout pregnancy, with ST V and ST
III colonisation lasting longer than other serotypes (ST V
mean duration 8.6 weeks; 95% CI 6.8e10.4 vs. ST III 9.2
weeks; 95% CI 8.1e10.2).3 The difference in serotype distri-
bution and duration of colonisation between these studies
may be due to population differences between South Africa
and the Gambia. There are no other longitudinal infant
colonisation studies with which to compare our results.
Our results may also indicate differences in maternally
derived antibody that might prevent colonisation of certain
serotypes in these diverse populations. In the most recent
study from South Africa, the authors demonstrate that it
is the acquisition of a new serotype that is associated
with EOS rather than the persistent serotype, probably
due to the absence of maternal antibody to this new
serotype.29
Our study has several limitations. First, our results are
limited by the sensitivity of detection of GBS on selective
media, estimated at 85%30 and by the fact that we identi-
fied the serotype by conventional PCR. This may imply that
we have underestimated low levels of colonisation in in-
fants where DNA was below the limit of detection. Second,
we identified only one culture-confirmed case of GBS inva-
sive disease. The low number of positive invasive isolates
Table 6 Single variable analysis of infant GBS colonisation dynamics over time compared to birth.
Birth
OR (95% CI)
Day 6 Day 60e89
OR (95% CI) OR (95% CI)
Mother GBS colonised at delivery
Birth season Dry cool 1 0.2 (0.1e0.6) 0.1 (0.0e0.4)
Dry hot 4.6 (2.2e9.7) 1.9 (1.0e4.1) 0.6 (0.2e1.3)
Wet 1.4 (0.7e2.8) 0.7 (0.3e1.5) 0.3 (0.1e0.7)
Living children 0 1 0.5 (0.3e0.9) 0.2 (0.1e0.4)
1e4 0.9 (0.5e1.6) 0.4 (0.2e0.7) 0.1 (0.0e0.3)
5þ 0.9 (0.3e2.6) 0.6 (0.2e1.8) 0.2 (0.0e0.9)
Gestation at birth (wks.) <34 1 0.4 (0.1e1.4) ND
34e37 0.9 (0.3e2.4) 0.3 (0.1e0.9) 0.2 (0.1e0.7)
38þ 0.4 (0.1e1.0) 0.2 (0.1e0.5) 0.0 (0.0e0.1)
Infant weight (kg) 2.5e3 1 0.5 (0.2e1.0) 0.1 (0.0e0.3)
3.1e4.0 1.2 (0.4e3.8) 0.7 (0.3e0.9) 0.1 (0.1e0.3)
>4.0 0.6 (0.1e2.3) 0.3 (0.1e0.7) 0.1 (0.0e0.6)
BM colonised Yes 0.9 (0.5e1.7) 0.4 (0.2e0.8) 0.3 (0.1e0.7)
No 1 0.4 (0.3e0.6) 0.1 (0.1e0.2)
Infant sex Male 1 0.4 (0.3e0.7) 0.1 (0.1e0.3)
Female 0.7 (0.4e1.2) 0.4 (0.2e0.6) 0.1 (0.1e0.3)
Mother not GBS colonised at delivery
Birth season Dry cool 1 1.4 (0.5e4.3) 0.8 (0.2e2.8)
Dry hot 1 1.3 (0.3e5.3) 4.7 (1.7e13.5)
Wet 2.1 (0.8e6.0) 4.1 (1.6e10.5) 0.2 (0.0e1.9)
Living children 0 1 1.8 (0.5e5.7) 1.7 (0.5e5.6)
1e4 1.0 (0.3e2.9) 2.2 (0.8e5.9) 0.7 (0.2e2.3)
5þ 2.0 (0.1e7.1) 1 0.8 (0.1e7.3)
Gestation at birth (wks.) <34 1 3.3 (0.3e34.4) 1
34e37 1.6 (0.2e13.4) 2.5 (0.3e20.6) 1.4 (0.2e13.0)
38þ 1.1 (0.1e9.0) 2.2 (0.3e17.3) 1.3 (0.2e10.8)
Infant weight (kg) 2.5e3.0 1 1.2 (0.4e3.8) 0.6 (0.1e2.3)
3.1e4.0 0.5 (0.2e1.4) 1.2 (0.5e2.9) 0.6 (0.2e1.7)
>4.0 0.9 (0.2e2.3) 1.7 (0.9e4.9) 0.4 (0.3e2.2)
BM colonised Yes 14.2 (4.0e50.8) 6.9 (2.5e19.1) 3.3 (1.2e11.0)
No 1 2.0 (0.9e4.2) 1.0 (0.4e2.5)
Infant sex Male 1 1.4 (0.6e3.1) 0.8 (0.3e2.0)
Female 0.3 (0.1e1.0) 1.1 (0.5e2.5) 0.5 (0.2e1.5)
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may represent an underestimation of the burden of GBS
disease in this population. Several infants died prior to
recruitment or after recruitment but of early onset pneu-
monia without a culture-positive diagnosis and it is
conceivable that they may have succumbed to early onset
GBS disease. There are no other data from the Gambia
regarding the burden of GBS disease. Although we recog-
nize the limitations of its approach, the only other evi-
dence for GBS disease in the Gambia is shown by a
retrospective review of positive cultures from the MRC
hospital over 8 years that identified 17 positive cultures
from infants under 90 days of age which is consistent
with our disease estimate of 1.3/1000 live births.31 Finally,
sampling at 4 h post-birth may indicate contamination
with maternal secretions rather than established colonisa-
tion at birth. However, the fact that few infants lost colo-
nisation at day 6 indicates that colonisation was persistent
over the first week of life.
GBS capsular polysaccharide-protein conjugate vaccines
are being developed, making the findings of our study
important to ensure that appropriate serotypes are
included in candidates that would be relevant to all African
populations. Information about GBS colonisation and fac-
tors affecting acquisition and duration of colonisation will





















































Figure 2 Colonising serotype distribution by isolation site and time point. Maternal rectovaginal colonisation at delivery; breast-
milk and infant colonisation by time point; BMZ breastmilk; IaZ serotype Ia, IbZ serotype Ib, IIZ serotype II, IIIZ serotype III,
V Z serotype V.
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be helpful in considering strategies for reducing the burden
of infant GBS disease worldwide.
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CONCISE COMMUNICATION
Placental transfer of anti-group B Streptococcus
immunoglobulin G antibody subclasses from
HIV-infected and uninfected women
to their uninfected infants
Kirsty Le Doarea,b,c, Stephen Taylord, Lauren Allend,
Andrew Gorringed, Paul T. Heathb, Beate Kampmanna,c,
Anneke C. Hesselinge and Christine E. Jonesa,b,f
Objectives: Placental antibody transfer is impaired in the context of HIV infection,
which may render HIV-exposed, uninfected infants vulnerable to group B Streptococ-
cus (GBS) disease. The GBS antibody response predominately consists of immunoglo-
bulin G2 (IgG2) antibody. Thus we determined whether concentration and placental
transfer of anti-GBS antibody subclasses was altered in HIV-infected compared with
HIV-uninfected mothers.
Design: A retrospective analysis of anti-GBS antibody subclasses in 38 HIV-infected
and 33 HIV-uninfected mothers and their uninfected infants.
Methods: Sera were analysed using a novel flow cytometric assay that quantified
binding of IgG1, IgG2, IgG3 and IgG4 to serotype (ST)Ia, STIII and STV GBS bacteria.
Results: IgG2 binding to GBS STIa and V was lower in HIV-infected women compared
with HIV-uninfected women. Moreover, IgG2 binding to GBS STIa was also lower in
HIV-exposed, uninfected infants compared with unexposed infants. However, there
were no statistically significant differences in the transplacental transfer ratio of IgG2 for
anyGBS serotype. The transplacental transfer of total IgGwas reduced for GBS STIII and
V and IgG1 subclass for STIII; placental transfer of all other subclasses was comparable
in HIV-affected and HIV-unaffected pregnancies.
Conclusion: Anti-GBS IgG2 placental transfer is not affected by HIV infection. This is
important for functional antibody against the capsular polysaccharide of GBS and
provides confidence that maternal GBS vaccination may result in functional activity in
HIV-infected and uninfected women.
Copyright ! 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Opsonophagocytosis of group B Streptococcus (GBS) is
mediated predominately by the immunoglobulin G2
(IgG2) subclass [1], which is poorly transported across the
placenta compared with IgG1 [2,3]. This may reflect the
lower affinity of IgG2 for the FcRn receptors on
syncytiotrophoblasts of placental cells as compared with
the other subclasses of IgG [4,5]. Studies comparing
maternal and infant antibody concentrations demonstrate
that anti-GBS capsular antibody is transferred across the
placenta with a high degree of efficiency [6]. However,
the proportionally higher concentration of antibody in
infant compared with maternal serum at birth is thought
to be mainly due to excess foetal IgG1 [2]. It has been
demonstrated for GBS serotype (ST) Ia and STIII that not
only is total anti-GBS antibody concentration lower in
GBS-infected infants than in infants without infection
born to colonized mothers [7,8], but that IgG2 is also
lower in infants with GBS infection [9]. Recent studies
have shown that maternal and placental transfer of total
anti-GBS antibody is reduced in the context of maternal
HIV-infection [10,11]. This might explain the greater
reported incidence of early, and especially late onset, GBS
disease observed amongst HIV-exposed, uninfected
infants compared with unexposed infants [12]. A West
African study identified hypergammaglobulinaemia as a
risk factor for reduced placental transfer of IgG subclasses
and this might be a further contributing factor to the
observed excess of GBS morbidity amongst HIV-exposed
infants [13]. Thus, we compared total and subclass anti-
GBS antibody placental transfer in HIV-infected and
HIV-uninfected South African women.
Methods
Samples were collected frommothers and infants enrolled
in a cohort study investigating the influence of maternal
HIV and mycobacterial sensitization on infant immune
responses to Bacillus Calmette-Gue´rin (BCG) vaccina-
tion carried out between 2009 and 2011 [14]. The
demographic details, CD4þ cell count, viral load and
antiretroviral medication have been previously described
[14]. Informed consent was obtained from all mothers
participating in the study. The study was approved by the
Universities of Cape Town (382/2008) and Stellenbosch
(N08/10/278), South Africa, and the National Health
Service Research Ethics Committee, England (07/
H0720/178).
Paired sera from 38 HIV-infected and 33 HIV-uninfected
mothers and their uninfected infants were available to
analyse immunoglobulin subclasses. Deposition of total
IgG and IgG1, IgG2, IgG3 and IgG4 anti-GBS antibody
subclasses onto the surface of formaldehyde-fixed GBS
bacteria was measured using a flow cytometric assay
performed in 96-well microtitre plates as previously
described [10]. Mouse monoclonal antibodies: 4E3
antihuman IgG1 H&L, HP6014 antihuman IgG2 fd
gamma, HP6050 antihuman IgG3 hinge heavy chain and
mouse HP6025 antihuman IgG4 Fc (FITC) (Life
Technologies, Carlsbad, California, USA) (1 : 500) in
blocking buffer were added and samples incubated for 20
min at 48C. Assays were analysed using a Beckman
Coulter Cyan flow cytometer equipped with a Cytek 96-
well microtitre plate loader. A fluorescence index (FI) was
calculated for each sample, which involved the multipli-
cation of the percentage of bacteria in the horizontal gate
(%-gated), by the mean fluorescence of that population
(X-mean). The final result for each test was expressed as
the average FI of duplicate test samples minus the average
FI of the bacteria and conjugate-only control. A standard
unit (SU) measurement for each serum sample was then
calculated by comparing to the serum FI response
obtained with the positive control serum for each
serotype which was given an arbitrary value of 1000
(kind gift from Professor Carol Baker, Baylor College of
Medicine, Texas, USA) to give a result in SU/ml.
Statistical analyses were completed using STATA version
12 (StataCorp 2013, College Station, Texas, USA) and
GraphPad Prism version 6.0 (GraphPad Software Inc., La
Jolla, California, USA). The sample size was calculated to
demonstrate a 50% difference in IgG subclass concen-
trations between HIV-exposed and HIV-unexposed
infants with the predefined assumption that antibody
subclass concentrations would be lower in HIV-exposed
infants. Using an a error of 5%, 80% test power and a 95%
confidence interval, the sample size ranged from 10 to 30
in each group. Placental transfer was defined as the ratio of
infant-to-mother GBS IgG concentration at birth.
Missing data were excluded from analysis. We considered
P values less than 0.05 as statistically significant.
Results
The paired sera from 71 mother–infant dyads (38 HIV-
infected mothers and their uninfected infants and 33
HIV-uninfected mothers and their infants) at birth were
available for analysis of total IgG, IgG1 and IgG2 for all
serotypes. For serotypes ST1a and STV, sufficient sera was
available from 60 mother–infant pairs to analyse
subclasses IgG3 and IgG4. Sufficient sera were available
from 40 mother–infant pairs for analysis of IgG3 and
IgG4 for STIII.
Antibody subclass concentrations
Concentrations of anti-GBS IgG1 in mothers and infants
were higher than concentrations of IgG2 for all GBS
serotypes, independent of HIV status (Fig. 1).
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For STIa, HIV-uninfected women had significantly
higher geometric mean concentration (GMC) of subclass
IgG2 and IgG4 than HIV-infected women (IgG2 2.3
[95% confidence interval (CI) 1.6–3.3] vs. 5.9 [4.0–8.9]
SU/ml, P¼ 0.02; IgG4 1.8 [0.9–3.6] vs. 18.6 [6.0–57.8]
SU/ml, P¼ 0.03) but comparable concentrations of IgG1
and IgG3 (Fig. 1). In HIV-unexposed compared with
HIV-exposed, uninfected infants, there was a significantly
higher concentration of IgG2 (P¼ 0.03) and IgG4
(P¼ 0.03). In addition, we noted a trend towards higher
concentrations of anti-STIa IgG1 and lower concen-
tration of IgG3 but this did not reach statistical
significance (Fig. 1).
For STV, HIV-infected women had a trend towards
higher concentrations of IgG1 than HIV-uninfected
women (P¼ 0.049) and HIV-uninfected women had
significantly higher concentrations of IgG2 than HIV-
infected women (P¼ 0.047), although the concentration
of IgG2 was low in both groups. HIV-unexposed infants
had higher concentrations of anti-STV IgG3 antibody
compared with HIV-exposed infants (P¼ 0.039). There
was no statistical difference between HIV-exposed,
uninfected infants and HIV-unexposed infants for any
of the other IgG subclasses (Fig. 1).
There was no significant difference between anti-STIII
IgG subclasses in HIV-infected and HIV-uninfected
women and HIV-exposed, uninfected and HIV-
unexposed infants.
Placental transport of total group B
Streptococcus antibody
Total IgG transplacental antibody transfer ratio (TPR)
was reduced in HIV-infected compared with HIV-
uninfected women for GBS STIII [0.6 (0.3–1.1) vs. 1.3
(0.8–2.3) SU/ml, P¼ 0.04] and STV [1.2 (0.7–1.6) vs.
2.0 (1.1–3.0) SU/ml, P¼ 0.04] but not for STIa. (Table
1). There was no association between CD4þ cell count or
viral load and TPR.
Placental transport of subclasses group B
Streptococcus antibody
TPR of IgG1 was decreased to HIV-exposed infants
compared with HIV-unexposed infants [0.4 (0.1–1.4) vs.


































































Fig. 1. Anti-group B Streptococcus subclass distribution in
HIV-infected and HIV-uninfected mothers and their unin-
fected infants at birth. HIV–, HIV uninfected; HIVþ, HIV
infected; IgG, immunoglobulin G; ST, serotype; SU/ml, stan-
dard units per millilitre. Horizontal bars compare groups,
#P<0.05.
Table 1. Geometric mean concentration (GMC) transplacental transfer ratios of total and subclass IgG1, IgG2, IgG3 and IgG4 against GBS STIa,
III and V in HIV-infected and HIV-uninfected mothers to their infants [95% confidence interval (CI)].
STIa STIII STV
HIVþ HIV– P HIVþ HIV– P HIVþ HIV– P
Total 1.1 (0.8–1.6) 1.0 (0.6–1.6) 0.75 0.6 (0.3–1.1) 1.3 (0.8–2.3) 0.04 1.2 (0.7–1.6) 2.0 (1.1–3.0) 0.04
IgG1 1.0 (0.7–1.5) 1.4 (1.0–2.0) 0.44 0.4 (0.1–1.4) 1.3 (0.7–2.5) 0.04 1.0 (0.7–1.4) 1.4 (0.9–2.1) 0.14
IgG2 0.9 (0.5–1.5) 0.7 (0.5–1.2) 0.43 1.1 (0.4–3.2) 0.8 (0.4–1.4) 0.38 0.7 (0.5–1.1) 0.8 (0.6–1.1) 0.59
IgG3 0.3 (0–9) 1.0 (0.3–3.3) 0.5 0.9 (0.6–1.4) 1.3 (0.8–2.1) 0.23
IgG4 0.5 (0.2–1.1) 1.6 (0–4) 0.08 1.2 (0.5–2.9) 0.6 (0.3–1.4) 0.31
GBS, group B Streptococcus; HIV–, HIV-uninfected; HIVþ, HIV infected; IgG, immunoglobulin G; ST, serotype.
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1.3 (0.7–2.5) SU/ml; P¼ 0.04] for STIII but not for STIa
or STV (Table 1). The TPR for IgG2 was unaffected by
maternal HIV infection status for any serotype. There
were no statistical differences between antibody TPR for
any other subclass or any other serotype of GBS between
groups.
Discussion
Our findings demonstrate that whilst total transplacental
transfer ratios are reduced in HIV-infected mothers for
GBS STIII and V, the proportion of individual subclasses
transferred from mother to infant is unaffected by
maternal HIV infection, with the exception of IgG1 to
GBS STIII. Importantly, there was no difference in the
placental transfer of IgG2 that bounds to any of the
GBS serotypes.
HIV-exposed, uninfected infants may be at increased risk
of GBS infection, in particular late onset disease [10,12]
The observation that there is no difference in the
proportion of IgG subclass placental transfer (except for
IgG1 for STIII) may mean that HIV-exposed, uninfected
infants are at increased risk of disease as a result of their
mother’s reduced total antibodies that bind to GBS
bacteria, rather than a selective deficit in IgG2 transfer. It
may alternatively be due to impaired B cell function in the
context of HIV infection that results from poor function
of T helper cellular response and function of antibody in
the context of HIV-infection [15].
The fact that IgG2 surface deposition was lower in HIV-
exposed infants to STIa and in women to STV in HIV-
infected women may indicate reduced antibody function
due toHIV-infection. In this studywewere unable to assess
the opsonophagocytic ability of the antibodywhich would
provide additional information on the functional ability of
antibody to protect from GBS infection. In studies of
pneumococcal vaccination, opsonophagocytosis was
impaired in HIV-infected compared with HIV-uninfected
individuals and the same may be true of GBS [16].
The serotypes we have selected in this study represent
77% of colonizing strains in South African pregnant
women (STIII, 33%; STIa, 39%; STV, 12% [17]). They
also represent 86.1% of early onset GBS disease and 100%
of late onset disease (STIII 57.7% of early onset, 84.4% of
late onset disease; STIa 22.6%/ 13.9%; STV 5.8%/1.9%
[18]). Thus, the serotype-specific antibody observed
corresponds to the predominant colonizing and disease-
causing serotypes in South Africa.
Although patients with HIV disease develop high levels of
total IgG in serum soon after infection [19], the IgG1
subclass is preferentially increased, whereas levels of total
IgG2may be normal or decreased [20].We confirmed the
relatively similar concentration of IgG2 antibody that
binds to GBS STIII in the sera of HIV-infected and HIV-
uninfected women. IgG2 responses to the bacterial
capsular polysaccharide in humans may be driven in part
by IFN-y production [21], whichmay be impaired during
HIV-infection [22]. However, HIV-infected patients in
our cohort showed no selective deficit in IgG2
production. The differences in subclass distribution by
GBS serotype may be as a result of different reactivity of
the different serotypes in our assay. However, comparison
with the larger study demonstrated good correlation
between total antibody concentrations for all serotypes
tested [10].
Maternal HIV infection has been associated with reduced
placental transfer of antibodies against several common
viral and bacterial antigens [23,24]. Additionally, the
finding that HIV-exposed, uninfected infants are more
likely to have sub-protective antibody levels to vaccine
preventable diseases means that these infants are likely to
be more prone to these diseases in early childhood. Our
finding that the placental transfer of IgG2 subclass,
important for the opsonization and killing of GBS, was
not impaired indicates potential for a maternal vaccine to
boost both maternal and infant immunity in areas of high
HIV-prevalence.
Our sample size was limited and we are not able to draw
conclusions on other possible effects of HIV-infection on
placental transfer. Additionally, we cannot comment on
the colonizing serotypes of the mothers. However, the
fact that the antibody against the major GBS serotypes was
detected in all women suggests prior colonization with
GBS. Finally, we cannot comment on protective levels of
antibody in this population, as there were no cases of GBS
disease in our cohort.
In summary, the decreased concentration of serum IgG that
bounds to the surface of GBS in HIV-infected women and
their infants comparedwith non-HIV-infected dyads is not
due to a selective defect in the generation of GBS-specific
IgG2 antibody. Future efforts should address enhancing
protective antibody concentrations through maternal
vaccination against GBS during pregnancy to optimize
IgG2 concentration in the neonate.
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a  b  s  t  r  a  c  t
Background:  HIV-exposed  uninfected  infants  have  increased  infection  risk  and  mortality  compared  to
HIV-unexposed  infants.  HIV-exposed  infants  may  be at  increased  risk  of  invasive  GBS  disease  due to
reduced  maternal  antibody  against  GBS.
Methods: We  quantified  antibodies  that  bind  to  the  surface  of  whole  Group  B  Streptococcus  (GBS) of
serotypes  Ia,  Ib,  II, III and  V  using  novel  flow  cytometry  assays  in  South  African  HIV-infected  and  non-
infected  mothers  and  their  uninfected  infants.  Antibody-mediated  complement  C3b/iC3b  deposition  onto
GBS of  these  serotypes  was  also  quantified  by  a novel  flow  cytometry  assay.
Results: Geometric  mean  concentration  (GMC)  of  both  surface-binding  anti-GBS  antibody  and  antibody-
mediated  complement  deposition  onto  GBS  were reduced  in  HIV-infected  women  (n  =  46)  compared  to
HIV-uninfected  women  (n  =  58)  for ST1a  (surface-binding:  19.3  vs 29.3;  p  =  0.003;  complement  depo-
sition:  2.9  vs  5.3  SU/mL;  p  =  0.003),  STIb  (24.9  vs  47.6;  p =  0.003;  2.6  vs 4.9  SU/mL;  p =  0.003),  STII (19.8
vs  50.0;  p = 0.001;  3.1  vs  6.2 SU/mL;  p =  0.001),  STIII  (27.8  vs  60.1;  p  = 0.001;  2.8  vs  5.3  SU/mL;  p =  0.001)
and  STV (121.9  vs  185.6 SU/mL;  p  <  0.001)  and  in  their  infants  for  STIa  (complement  deposition  9.4 vs
27.0  SU/mL;  p = 0.02),  STIb  (13.4  vs  24.5  SU/mL;  p  =  0.02),  STII  (14.6  vs  42.7  SU/mL;  p  = 0.03),  STIII  (26.6 vs
62.7  SU/mL;  p = 0.03) and  STV  (90.4  vs  165.8  SU/mL;  p = 0.04).  Median  transplacental  transfer  of  antibody
from  HIV-infected  women  to their  infants  was reduced  compared  to HIV-uninfected  women  for  GBS
serotypes  II  (0.42  [IQR  0.22–0.59]  vs 1.0  SU/mL  [0.42–1.66];  p < 0.001),  III  (0.54  [0.31–1.03]  vs  0.95  SU/mL
[0.42–3.05],  p  =  0.05)  and V  (0.51  [0.28–0.79]  vs 0.75  SU/mL  [0.26–2.9],  p =  0.04).  The differences  between
infants  remained  significant  at 16  weeks  of age.
Conclusions:  Maternal  HIV  infection  was  associated  with  lower  anti-GBS  surface  binding  antibody  con-
centration  and  antibody-mediated  C3b/iC3b  deposition  onto  GBS  bacteria  of serotypes  Ia, Ib,  II,  III and  V.
This  may  render  these  infants  more  susceptible  to  early  and  late onset  GBS  disease.
Crown  Copyright  © 2014  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The increasing numbers of HIV-exposed infants who remain
uninfected is testament to the success of prevention of mother-to-
child transmission programs in resource-poor settings in the face
! Preliminary data was presented at the European Society of Infectious Diseases
meeting May  2014, Dublin, Ireland.
∗ Corresponding author at: Wellcome Trust/Imperial Centre for Global Health
Research, Department of Paediatrics, Imperial College London, Norfolk Place, London
W2  1PG, UK. Tel.: +44 2075895111; fax: +44 207 5895111.
E-mail address: k.mehring-le-doare@imperial.ac.uk (K. Le Doare).
of a high disease burden [1]. Nevertheless, this group of infants
appears to suffer from increased rates of lower respiratory tract
infection and meningitis compared to HIV-unexposed infants and
up to 4-fold higher mortality in the first year of life [2–4]. Strepto-
coccus agalactiae (group B streptococcus, GBS) is a leading cause of
neonatal pneumonia, sepsis and meningitis in many countries and
five serotypes (Ia, Ib, II, III and V) account for the majority of disease
[5]. Published data show that not only is GBS carriage increased
in HIV-infected pregnant women  compared with HIV-uninfected
mothers [6], but that HIV-exposed, uninfected infants also appear
to have an increased risk of late-onset GBS disease compared to
HIV-unexposed infants [7].
http://dx.doi.org/10.1016/j.vaccine.2014.12.025
0264-410X/Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Prevention of GBS infection in infants and adults through immu-
nization is a theoretically attainable goal. Maternal transfer of
antibodies is thought to prevent newborn GBS disease [8] and
GBS vaccines offer the potential to prevent disease in low-income
settings where prenatal screening and intrapartum antibiotics are
generally not feasible. A number of studies have demonstrated
an association between the risk of developing invasive GBS dis-
ease in the newborn and maternal anti-capsular antibody levels
[9–12] with opsonophagocytosis the likely effector mechanism
[13–15]. However, maternal HIV status can influence the effi-
ciency of transplacental antibody transfer, resulting in reduced
maternally-derived specific antibody concentration in the infant,
even where the infant is subsequently HIV uninfected [16–19].
Data regarding the persistence of anti-GBS antibodies in popula-
tions with high HIV-prevalence and their function in vitro would
provide insight into their protective potential in different popula-
tions. Thus our objective was to determine the association between
maternal HIV infection status and total IgG binding to the surface of
GBS bacteria of serotypes Ia, Ib, II, II and V and antibody-mediated
deposition of C3b/iC3b onto the surface of these GBS strains as a
potential surrogate for opsonophagocytosis in sera obtained from
mothers and infants.
2. Methods
2.1. Study setting, eligibility and study measures
Samples were collected from mothers and infants enrolled in
a cohort study investigating the influence of maternal HIV and
mycobacterial sensitization on infant immune responses to BCG
vaccination carried out between 2009 and 2011 [20]. In brief, 109
pregnant women presenting to a Community Health Center in
Khayelitsha, Western Cape Province, South Africa who  delivered
a healthy infant over 37 weeks gestation, weighing over 2.5 kg,
knew the result of their HIV test and were willing to provide
written informed consent for themselves and their infants were
recruited to the original study. The subset represented all moth-
ers/infants with available samples. A venous blood sample was
collected from the mother and infant within 24 h of delivery.
All infants had a further venous blood sample collected at 16
weeks. HIV-exposed infants had an HIV polymerase chain reaction
(Amplicor HIV-a DNA kit, version 1.5; Roche Molecular Systems
Inc., Branchburg, NJ) performed at ages 4 and 16 weeks. The study
was approved by the Universities of Cape Town (382/2008) and
Stellenbosch (N08/10/278), South Africa, and the National Health
Service Research Ethics Committee, England (07/H0720/178).
In 2009, the HIV prevalence among women attending antenatal
clinics in the area was 31% [21]. During the study period, the Pre-
vention of Mother to Child Transmission program consisted of dual
therapy for mothers and infants, starting with the administration
of zidovudine at 28 or more weeks’ gestation, then zidovudine for 1
month to the infant and a single dose of nevirapine to both mother
and infant. Mothers were eligible for highly active antiretroviral
treatment if their CD4 count was less than 200 cells/!L. Exclu-
sive infant feeding options were encouraged and mothers were
provided with free formula for 6 months if they chose exclusive
formula feeding.
2.2. Laboratory assays
The reproducibility of the assays was assessed between three
different days and between three different operators with a panel
of 18 sera. The assays had a coefficient of variation of less than
30%. Controls used were rabbit polyclonal sera (SSI) raised against
serotypes Ia, Ib, II, III & V, and normal human donor sera.
2.2.1. GBS isolates and growth conditions
Group B Streptococcus isolates used in this study were
H092040676 (Serotype Ia), H090820125 (Serotype Ib),
H090320548 (Serotype II), H092120162 (Serotype III) and
H091780506 (Serotype V), which were kindly provided by
Professor Androulla Efstratiou, Public Health England, Colindale.
Strains are subsequently referred to by their serotype.
GBS isolates used in the antibody surface binding and comple-
ment deposition assays were grown in Todd Hewitt broth at 37 ◦C
with shaking (200 rpm). Once OD600nm 1.0 was reached, cultures
were centrifuged at 3060 × g for 5 min  to pellet the bacteria. The
pellet was  re-suspended in the same volume of phosphate buffered
saline (PBS, pH 7.4, Severn Biotech, UK) containing 2% formalde-
hyde and incubated at room temperature for 1 h. Bacteria were
then washed in PBS by three rounds of centrifugation at 3060 × g
for 5 min  and resuspended. The final cell pellet was resuspended in
1 mL  PBS, which was stored at 4 ◦C before use.
2.2.2. Sample preparation for antibody surface binding assay
Deposition of anti-GBS antibody onto the surface of whole
GBS bacteria was  measured on formaldehyde-fixed GBS using a
flow cytometric assay performed in 96-well microtitration plates.
Briefly, 2 !L of each test serum was  added to 198 !L of serotype Ia,
Ib, II, III or V GBS bacteria at 5.14 × 107 CFU/mL in blocking buffer
(1% BSA in PBS). This was incubated at 25 ◦C for 30 min with shaking
(900 rpm), then pelleted. Supernatant was removed and the pel-
let washed twice with 200 !L of blocking buffer. Alexa Fluor® 488
Goat Anti-Human IgG (H&L) (Life Technologies) (1:500) in blocking
buffer was added and samples incubated for 20 min  at 4 ◦C, before
being washed twice more with blocking buffer.
2.2.3. Sample preparation for antibody-mediated complement
C3b/iC3b deposition assay
Antibody-mediated C3b/iC3b deposition on the surface of whole
GBS bacteria was measured on the surface of formaldehyde-fixed
GBS using a flow cytometric assay performed in 96-well microtitra-
tion plates. Briefly, 35 !L serotype Ia, Ib, II, III and V GBS bacteria at
5.14 × 107 CFU/mL in blocking buffer (1% BSA in PBS) were added
to 10 !L IgG-depleted human complement [22] and 5 !L of each
test serum. Plates were incubated for 7.5 min  at 37 ◦C with shak-
ing (900 rpm) then pelleted. Supernatant was removed and the
pellet washed once with 200 !L blocking buffer. Samples were
resuspended in 200 !L blocking buffer containing 1:500 sheep anti-
human C3c FITC (Abcam) and incubated as for the surface binding
assay.
2.2.4. Sample acquisition
Assays were analyzed using a Beckman Coulter Cyan flow
cytometer equipped with a Cytek 96-well microtitre plate reader.
Protocols were initially set-up to analyze profiles of bacterial events
using bacteria-only control samples and the bacteria identified on
the cytometer by the forward scatter (FS), measuring the size of the
cell, and side scatter (SS), the granularity and internal structural
complexity. An analysis ‘gate’ was  drawn around the population
of interest (single and diplococci) and a relevant histogram plot
created to analyze the fluorescence of the bacterial population.
For each sample, 10,000 individual events were analyzed for flu-
orescence and a horizontal gate was  drawn to include 10% of the
‘no antibody’ control population. A fluorescence index (FI) was
calculated for each sample, which involved the multiplication of
the percentage of bacteria in the horizontal gate (%-gated), by the
mean fluorescence of that population (X-mean). The final result
for each test was expressed as the average FI of duplicate test
samples minus the average FI of the bacteria and conjugate-only
control. A standard unit (SU) measurement for each serum sam-
ple was then calculated by comparing to the serum FI response
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obtained with the positive control serum for each serotype which
was given an arbitrary value of 1000 (kind gift from Professor
Carol Baker, Baylor College of Medicine, Texas) to give a result in
SU/mL.
2.3. Data management and statistical analysis
Sample size was determined for the cohort study; this sub-study
had 80% power (p = 0.05) to investigate differences between anti-
body concentrations in HIV-exposed and HIV-unexposed infants
of at least 30% with the pre-specified hypothesis that the con-
centrations would be lower in HIV-exposed infants. This assay is
currently being formally compared with ELISA and opsonophago-
cytosis uptake assays in another study.
Statistical analyzes were completed using STATA version 12
(StataCorp 2013, La Jolla, CA) and GraphPad Prism version 6.0
(GraphPad Software Inc., La Jolla, CA). Due to the skewed distribu-
tion of the anti-GBS antibody concentrations, log transformations
were required to conform to regression assumptions. A paired t-test
was used to determine any difference in anti-GBS-antibody con-
centrations to each GBS serotype between birth and at 16 weeks.
Comparison of infant anti-GBS antibody concentrations by mater-
nal HIV status was calculated using the Wilcoxon rank sum test.
Correlation of infant anti-GBS antibody concentration to each GBS
serotype at birth and at 16 weeks was assessed using Spearman
correlation. Multiple linear regression was used to ascertain the
relationship between infant anti-GBS antibody concentration to
each GBS serotype and the covariates of maternal age, infant sex
and maternal HIV. In addition, multiple linear regression was used
to explore the relationship between maternal anti-GBS antibody
concentration to each serotype and the covariates maternal age,
maternal HIV status. Placental transfer was defined as the ratio
of infant-to-mother anti-GBS IgG concentration at birth. Missing
data were excluded from analysis. Decline in antibody concentra-




Samples were analyzed from 104 women (46 (44%) HIV-infected
and 58 (56%) HIV-uninfected women) and from 100 infants born to
this group of women (46 (46%) HIV-exposed and 54 (54%) HIV-
unexposed infants). One mother–infant pair was  excluded from
the final analysis because HIV-infection in the infant was  detected
at 4 weeks of age and the infant was referred for rapid initiation
of antiretroviral treatment. All other infants born to HIV-infected
mothers were HIV-uninfected. All infants were born after 37 weeks
gestation. Follow-up samples at 16 weeks were available for 93
infants (93%; 38 HIV-exposed and 55 HIV-unexposed) at a mean
postnatal age of 16.4 weeks (SD = 1.7).
All HIV-infected women chose exclusive formula replacement
feeding. The median (IQR) CD4 count among the HIV-infected
women was 411.5 (293.9–604.0) cells/!L and the median (IQR)
viral load was 800 (357–6000) copies/mL Seven women had CD4
counts of less than 200 cells/!L; three of these were taking
highly active antiretroviral treatment at enrollment and four were
referred to commence highly active antiretroviral treatment fol-
lowing delivery. Further characteristics of the study cohort have
been described previously [20]. At the time of the study, local
GBS disease incidence in Cape Town was reported at 0.67/1000
live births in a population with 24% of these infants being HIV-



















STIa STIb STII STIII STV
Fig. 1. Reverse cumulative distribution curve of maternal anti-GBS IgG surface bind-
ing by serotype concentrations (SU/mL). Curve demonstrates the percentage of the
total population with each antibody concentration for each of the five GBS serotypes.
ST,  serotype; SU/mL, standard units/mL
3.2. Maternal anti-GBS-antibody to GBS serotypes Ia, Ib, II, III and
V
All maternal sera had measurable geometric mean concentra-
tions (GMC) of antibody to at least one serotype. The distribution
of mothers’ antibodies that bound to the surface of GBS serotypes
Ia, Ib, II, III and V is shown in Fig. 1. The predominant surface bind-
ing anti-GBS-antibody was  against serotype V, followed by II, III, Ib
and Ia (Fig. 1).
Women  with HIV infection had significantly lower GMC  anti-
body concentrations to all five serotypes at delivery compared to
HIV-uninfected women (Fig. 2 and Table 1). There were no asso-
ciations between CD4 count and viral load on anti-GBS antibody
concentration by serotype in HIV-infected women.
The concentrations of antibody-mediated complement
C3b/iC3b deposition by GBS serotype are shown in Table 2.
The GMC  of antibody-mediated C3b/iC3b deposition was  signifi-
cantly greater in HIV-uninfected than HIV-infected women  for all
serotypes. The GMC  of antibody-mediated C3b/iC3b deposition
ranged from 4.9 SU/mL (serotype III) to 6.17 SU/mL  (serotype V)
in HIV-uninfected women  and from 2.6 SU/mL (serotype Ib) to
3.4 SU/mL (serotype V) in HIV-infected women.
3.3. Association of maternal HIV infection with placental transfer
of anti-GBS antibody
There was a positive correlation between paired maternal and
infant surface binding antibody concentrations for all serotypes (Ia,
r2 = 0.63, p < 0.001; Ib, r2 = 0.71, p < 0.001; II, r2 = 0.17, p < 0.001; III,
r2 = 0.35, p < 0.001; V, r2 = 0.16, p < 0.001). HIV-infected women had
significant reductions in placental transfer of anti-GBS serotypes II
and V compared with HIV-uninfected women (Table 3). There was
no association between CD4 count or viral load on transplacental
transfer ratios.
3.4. Infant anti-GBS-antibody by serotype at birth to GBS
serotypes Ia, Ib, II, III and V
HIV-exposed uninfected infants had significantly lower GMCs
of anti-GBS surface binding antibodies to all serotypes than unex-
posed infants (Fig. 3 and Table 1). In a multiple regression model
maternal HIV-status remained significant (p < 0.05).
However, there were no significant associations found between
infant anti-GBS-antibody concentrations to each serotype and
maternal age or infant sex.
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Fig. 2. Maternal anti-GBS surface binding IgG to GBS serotypes Ia, Ib, II, III and V concentrations at delivery (SU/mL). ST indicates GBS serotype. HIV indicates human
immunodeficiency virus. Horizontal lines indicate GMC  response.
Table 1
Geometric mean surface binding antibody concentrations (95% confidence intervals) in HIV-infected and HIV-uninfected mothers and their infants at birth and at 16 weeks
of  age.
STIa STIb STII STIII STV
HIV+ mother 19.3 (12.7–29.3) 24.9 (19.6–31.6) 21.8 (13.4–35.7) 27.8 (15.9–48.6) 121.9 (88.0–169.0)
HIV−  mother 37.0 (24.8–55.2) 47.6 (33.3–68.1) 50.0 (28.7–87.0) 60.1 (36.0–100.5) 185.6 (126.4–272.4)
HIV-exposed infants (birth) 9.4 (6.1–14.5) 13.4 (9.6–18.7) 14.6 (8.1–26.3) 26.6 (17.8–39.8) 90.4 (61.16–133.6)
HIV-unexposed infants (birth) 27.0 (16.5–44.3) 24.5 (16.4–36.5) 42.7 (23.4–77.8) 62.7 (38.1–103.1) 165.8 (112.0–245.4)
HIV-exposed infants (16 w) 7.0 (3.8–13.0) 8.7 (6.3–12.1) 17.6 (8.5–36.3) 48.0 (28.3–81.3) 68.54 (38.0–123.6)
HIV-unexposed infants (16 w)  21.6 (13.6–34.2) 14.9 (10.6–21.1) 68.3 (38.8–120.3) 97.4 (63.0–150.7) 180.2 (106.3–305.4)
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected; 16 w,  16 weeks of
age.
Table  2
Geometric mean concentration of antibody-mediated C3b/iC3b deposition (95% confidence intervals) on GBS serotypes Ia, Ib, II, III and V in HIV-infected and HIV-uninfected
mothers and their infants at birth.
STIa p value STIb p value STII p value STIII p value STV p value
HIV+ mother 2.9 (2.3–3.6) 2.6 (1.9–3.2) 3.1 (2.4–3.9) 2.8 (2.2–3.6) 3.4 (2.8–4.2)
HIV−  mother 5.3 (4.6–6.2) 0.003 4.9 (4.2–5.4) 0.003 6.2 (5.6–6.8) 0.001 5.3 (4.5–6.2) 0.001 6.2 (4.9–6.9) <0.0001
HIV-unexposed infants 6.1 (5.9–6.3) 5.9 (4.6–6.2) 6.9 (5.6–7.2) 6.6 (6.4–6.7) 6.3 (5.8–6.9)
HIV-exposed infants 3.8 (3.0–4.8) 0.02 3.1 (3.0–4.1) 0.02 4.2 (3.9–4.9) 0.02 3.9 (3.1–5.0) 0.03 4.2 (3.3–5.4) 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; HIV+, HIV infected; HIV−, HIV uninfected.
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Table  3
Influence of maternal HIV-infection on transplacental transfer of anti-GBS surface binding antibody to GBS serotypes Ia, Ib, II, III and V.
GBS serotype HIV-infected mothers: infants (IQR) HIV-uninfected mothers: infants (IQR) % Reduction in HIV-infected p value
STIa 0.66 (0.34–0.99) 0.6 (0.39–0.96) 0% 0.86
STIb  0.48 (0.17–0.88) 0.52 (0.32–0.78) 8% 0.48
STII  0.42 (0.22–0.59) 1.0 (0.42–1.66) 58% <0.001
STIII  0.54 (0.31–1.03) 0.95 (0.4–3.05) 43% 0.05
STV  0.51 (0.28–0.79) 0.75 (0.26–2.9) 32% 0.04
STIa, GBS serotype Ia; STIb, GBS serotype Ib; STII, GBS serotype STII; STIII, GBS serotype III; STV, GBS serotype V; IQR, interquartile range; HIV+, HIV infected, HIV−, HIV
uninfected; 16 w,  16 weeks of age.
Significantly lower GMC  of antibody-mediated C3b/iC3b depo-
sition was noted amongst HIV-exposed infants compared to
HIV-unexposed infants for all serotypes (Table 2). Notably, the GMC
of antibody-mediated C3b/iC3b deposition was higher in infants
than in their mothers for all serotypes.
3.5. Infant anti-GBS antibody at 16 weeks of age
Anti-GBS surface binding antibody GMCs remained significantly
lower at 16 weeks in HIV-exposed uninfected infants compared to
unexposed infants for all serotypes (Table 1). HIV-exposed infants
had significantly slower median rate of antibody decline com-
pared to HIV-unexposed infants at 16 weeks compared to birth to
STII (ratio of decline 1.03 [IQR −0.35 to 4.6] vs 0.21 SU/mL [−0.62
to 0.54], p = 0.04) and STIII (1.53 [−0.21 to 5.36] vs −0.09 SU/mL
(−0.60 to 0.93), p = 0.03) but not to ST1a (−0.12 [IQR −0.64 to
0.13] vs −0.04 [−0.39 to 0.45]), ST1b (−0.52 [−0.65 to 0.46]
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4. Discussion
Our findings demonstrate that total surface binding and func-
tional maternal antibody concentration to each of the GBS
serotypes (Ia, Ib, II, III and V) is lower at delivery in HIV-infected
women compared to their HIV-uninfected peers. Further, for three
of the five serotypes (II, III, V) the transplacental transfer ratio
was significantly lower from HIV-infected women to their unin-
fected infants. It follows therefore that infants born to HIV-infected
women had lower anti-GBS surface binding antibody concentra-
tions at birth for all serotypes; this difference was still evident at
16 weeks of age. The implication of our findings is that HIV-exposed
infants may  be more vulnerable to early and late onset GBS disease
than infants born to HIV-uninfected mothers.
Rectovaginal colonization with GBS is more frequent in HIV-
infected women compared to HIV-uninfected women [6,24].
Maternal colonization is the major risk factor for infant acquisi-
tion at birth and for early onset GBS disease. Thus infants born
to HIV infected mothers may  have both increased susceptibility
and increased exposure. It is generally understood that mater-
nal colonization stimulates maternal immunity; thus the finding
of lower maternal antibody concentrations despite higher colo-
nization rates suggests impairment of anti-GBS-specific antibody
production. This is also seen with polysaccharide-specific antibody
production in HIV-infected adults, such as in pneumococcal dis-
ease [25]. The fact that HIV-infected women have higher rates of
GBS colonization than HIV-uninfected women may  mean that anti-
body production secondary to colonization with GBS is deficient in
the context of maternal HIV-infection increasing the risk of invasive
GBS disease in HIV-exposed infants.
It is difficult to correlate our anti-GBS antibody results with what
is known regarding maternal colonization and infant GBS disease in
this South African population. However, the highest concentrations
of antibodies in women at delivery were to STV and III bacteria. The
latter is consistent with the known predominance of STIII among
carried strains in South African women (37%) but STV is carried by
a minority of women (10%) [24,26]. In our cohort the lowest lev-
els of antibody were to STIa bacteria, which is consistent with an
increased incidence of disease due to this serotype [26]. Our find-
ings may  suggest differences in the immune response to different
colonizing serotypes.
It is likely that lower maternal antibody concentrations and
altered transplacental transfer of antibody in HIV infection play a
role in the increased susceptibility to infectious diseases in infancy
[19,27], but there is a lack of data on the impact of maternal HIV
infection on neonatal infections in general, including GBS infec-
tions [28]. Infant anti-GBS surface binding antibody by serotype
remains lower at 16 weeks in HIV-exposed, uninfected infants,
who might therefore be more vulnerable to late onset GBS disease.
This corresponds to recent data from Cape Town which suggest
that 56% of GBS disease occurred after 7 days of life in a popula-
tion where one in four infants were HIV-exposed [23]. Apart from
the reduced passive immunity provided by maternal antibody in
the context of maternal HIV infection it might be that there are
differences in the immune response to infection of HIV-exposed,
uninfected infants secondary to in utero HIV exposure, as some data
suggest that these infants have altered lymphocyte differentiation
and function despite remaining HIV-uninfected [29,30]. However,
how this corresponds to clinical infection in the neonatal period is
not known.
Our findings are consistent with studies that demonstrate the
higher risk of infectious morbidity and mortality in HIV-exposed
infants compared to HIV-unexposed infants [31–33]. Recent South
African studies demonstrated a high prevalence of neonatal GBS
disease in a population with a high HIV burden [23,24,34]. A Study
from Malawi also demonstrated high rates of early and late onset
GBS infection in a population with high HIV prevalence [35]. In
contrast, one study from the USA did not find evidence of increased
susceptibility to GBS infection in HIV-exposed, uninfected infants
suggesting either regional screening and treatment differences
for both HIV infection and GBS carriage or population-based dif-
ferences in late onset GBS disease that might be unrelated to
HIV-status [36].
Our study has some limitations. Firstly, we  did not assess col-
onization in the mothers participating in the study and thus were
unable to correlate antibody responses to maternal colonization.
Whilst no infant developed early or late onset sepsis or meningitis
during the study, our sample size was also too small to detect this
as a valid endpoint and this was  not the aim of the study.
The use of two novel flow cytometric assays that quantify anti-
body binding to the surface of GBS bacteria and antibody-mediated
C3b/iC3b deposition on the bacterial surface may provide a more
complete assessment of antibody function than the measurement
of anti-polysaccharide IgG alone. However, the response measured
is not wholly serotype-specific as part of the antibody binding is
to cell wall proteins as well as the polysaccharide capsule. Despite
this, we see a serotype-specific response with a clear differentia-
tion between the distribution of antibody binding to the different
serotypes.
The potential of a trivalent maternal GBS vaccine encompass-
ing the major disease-causing serotypes (Ia, Ib, III) [8] to protect
against neonatal disease remains promising. However, it is vital
that ongoing evidence to support its use in vulnerable populations
with high HIV-prevalence is collected in order to support immu-
nization strategies in Sub-Saharan Africa.
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Streptococcus agalactiae (group B streptococcus [GBS]) is the leading cause of neonatal sepsis and meningitis. In this study, we
determined antibody-mediated deposition of complement C3b/iC3b onto the bacterial cell surface of GBS serotypes Ia, Ib, II, III,
and V. This was determined for 520 mother and umbilical cord serum sample pairs obtained at the time of birth from a popula-
tion on the Thailand-Myanmar border. Antibody-mediated deposition of complement C3b/iC3b was detected to at least one se-
rotype in 91% of mothers, despite a known carriage rate in this population of only 12%. Antibody-mediated C3b/iC3b deposi-
tion corresponded to known carriage rates, with the highest levels of complement deposition observed onto the most prevalent
serotype (serotype II) followed by serotypes Ia, III, V, and Ib. Finally, neonates born to mothers carrying serotype II GBS at the
time of birth showed higher antibody-mediated C3b/iC3b deposition against serotype II GBS than neonates born to mothers
with no serotype II carriage. Assessment of antibody-mediated C3b/iC3b deposition against GBSmay provide insights into the
seroepidemiology of anti-GBS antibodies in mothers and infants in different populations.
Group B streptococcus (GBS) (Streptococcus agalactiae) is anatural commensal of the vagina and rectum and is normally
carried asymptomatically (1). However, it is also the leading cause
of neonatal sepsis and meningitis in developed countries and is
associated with a highmortality rate with early-onset disease (0 to
6 days postbirth) and high morbidity in survivors of late-onset
GBSmeningitis (2, 3). Prophylactic treatment with antibiotics has
been introduced in the United States and Australia, greatly reduc-
ing the incidence of early-onset disease in those countries (4, 5).
However, the incidence of late-onset disease (defined as occurring
between 7 and 90 days after birth) has not decreased (5). In late-
onset neonatal sepsis (LONS), GBS may be acquired horizontally
from the community, making it harder to target the source of
infection (6, 7).
Natural antibodies toGBS are transferred frommother to baby
in utero beginning at 17 weeks (passive transport) and by active
transport during the third trimester of pregnancy, and they are
thought to protect the neonate from disease. Several clinical fac-
tors affect the likelihood of developing neonatal sepsis, including
prematurity (8, 9), as premature babies have reduced specific an-
tibodies due to the reduced time for transfer frommother to baby.
Determination of the protective levels of antibody required to
prevent GBS infection in neonates would greatly facilitate the
evaluation and effective use of new vaccines. Effective vaccination
would reduce the long-term costs of treatment of infected neo-
nates; the health care costs of infants that acquire neonatal GBS
infection are estimated to be roughly double those of control ne-
onates matched for age and birth weight (10). Furthermore, effec-
tive vaccination will reduce the likelihood of emergence of antibi-
otic-resistant strains (11).
Functional immunity to GBS has been demonstrated in an
opsonophagocytosis killing assay (OPKA) that measures the anti-
body and complement-dependent uptake and killing of bacteria
by human phagocytes (12, 13). Human vaccine sera with positive
OPKA activity have also been shown to passively protect mice in a
maternal passive protection/infant challenge model (14). OPKA
assays are generally laborious to perform and require large vol-
umes of test sera. Reliance on human donor phagocytes intro-
duces an extra variable, although this has been addressed with the
use of the humanphagocytic cell lineHL60 (15). Additionally, this
HL60-based OPKA has been adapted to measure the uptake of
fluorescently labeled bacteria by flow cytometry, thus removing
the extra plating and counting required for assay analysis (16). A
fluorescence opsonophagocytosis assay (fOPA) was developed
that measures both the uptake of bacteria and the functional re-
spiratory activity of the HL60 cells in a 96-well format (17). How-
ever, OPKA and fOPA require considerable resources to perform
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large studies, and minimizing the sample volume required is im-
portant, particularly for infant studies.
We evaluated the antibody-mediated deposition of comple-
ment C3b/iC3b onto bacteria representing five GBS serotypes
with 534 serum sample pairs frommother and cord blood samples
fromapopulation located on theThailand-Myanmar border (18).
This was evaluated using flow cytometry, and as opsonization of
bacteria by antibody and complement is required for uptake and
killing by phagocytic cells, this may be a surrogate for op-
sonophagocytosis.
MATERIALS AND METHODS
Sample collection. The study population was described by Turner et al.
(18). In brief, mothers enrolled in the study were residents of the Maela
refugee camp located on the Thailand-Myanmar border. Inhabitants were
mostly Karen refugees, with a total population of approximately 43,000.
Around 1,500 deliveries occur in the camp every year, and all antenatal
care is provided by the Shoklo Malaria Research Unit. A total of 549
women were enrolled in the study at 28 to 30 weeks’ gestation. Venous
blood samples were collected from themothers and umbilical cords at the
time of birth. Of the sera collected, a total of 543 serum samples from
mothers and 525 serum samples from umbilical cords were available for
this study. Data were also collected on the GBS carriage status of the
mother at the time of birth, which was assessed by culture of vaginal and
rectal swabs (18).
Study ethics. All women gave informed consent to participate in the
study. Ethical approval was granted by the ethics committee of the Faculty
of Tropical Medicine, Mahidol University, Thailand (MUTM 2009-011-
03) and the Oxford Tropical Research Ethics Committee, Oxford Univer-
sity, United Kingdom (48 08).
GBS isolates and growth conditions. Group B streptococcus isolates
used in this study were geographically diverse United Kingdom clinical
isolates from neonatal blood cultures. H092040676 (serotype Ia),
H090820125 (serotype Ib), H090320548 (serotype II), H092120162 (se-
rotype III), and H091780506 (serotype V) were kindly provided by
Androulla Efstratiou, Public Health England, Colindale. Throughout the
article, strains are referred to by their serotype.
GBS isolates used in the complement deposition assay were grown in
Todd-Hewitt broth at 37°C with shaking (200 rpm). Once an optical
density at 600 nm (OD600) of 1.0 was reached, cultures were centrifuged at
3,060! g for 5min to pellet the bacteria. The pellet was resuspended in the
same volume of phosphate-buffered saline (PBS, pH 7.4; Severn Biotech,
United Kingdom) containing 2% formaldehyde and incubated at room
temperature for 1 h. Bacteria were then washed in PBS by 3 rounds of
centrifugation at 3,060! g for 5min and resuspended. The final cell pellet
was resuspended in 1 ml PBS, which was stored at 4°C before use.
Production of IgG-depleted human complement. Human comple-
ment used in the complement deposition assay was produced as described
previously (19). Briefly, bloodwas collected fromvolunteers into contain-
ers with 50 "g/ml lepirudin (Movianto, United Kingdom). Plasma was
then removed, pooled, and depleted of IgG by protein G Sepharose affin-
ity chromatography. Aliquots were stored at#70°C until use.
Antibody-mediated complement C3b/iC3b deposition assay. Com-
plement deposition assays were performed in 96-well plates, and each test
serum sample was analyzed at a single dilution. To each well, 5 "l sera
(10% final concentration) was added, followed by 10 "l IgG-depleted
human complement (20% final concentration) and 35 "l fixed bacteria
(1.8! 106 CFU/well). The bacteria were resuspended in blocking buffer
(BB) (PBS containing 1% bovine serum albumin [BSA]; Sigma, United
Kingdom). Controls included samples of bacteria only and bacteria and
complement only, which were made to the same volume using BB. Pre-
activated zymosan (1.8 ! 106 particles/well; CompTech, USA) was also
used as a control to normalize for day-to-day variation. The plate was
incubated for 7.5 min at 37°C with shaking at 900 rpm. Plates were then
centrifuged at 3,060 ! g for 5 min, and the supernatant was removed,
ensuring that the bacterial pellet was not disturbed. Pellets were washed
with 200 "l BB and then centrifuged at 3,060 ! g for 5 min, and the
supernatant was removed, ensuring that the bacterial pellet was not dis-
turbed. Each pellet was then resuspended in 200 "l BB containing rabbit
anti-humanC3c conjugated to fluorescein isothiocyanate (FITC) at 1/500
(Abcam, United Kingdom), which binds to both C3b and iC3b, and the
plate was incubated at 4°C for 20 min. The plate was centrifuged at
3,060 ! g for 5 min, and the bacterial pellet was washed twice in BB, as
performed previously. Finally, the pellet was resuspended in 200 "l BB
and kept at 4°C until analysis by flow cytometry.
Data collection and analysis. Samples were analyzed on a CyAn ADP
flowcytometer (BeckmanCoulter, Inc.)with an automatedmicrosampler
system (Cytek Development, Inc.). Data were acquired in a Summit 4.3
(BeckmanCoulter, Inc.), and 5,000 events were obtained for each sample.
This was performed by setting a gate that contained 10% of the events
detected with the control containing bacteria and complement only. A
fluorescence index (FI), which was calculated by multiplying the number
of events in the gate noted above and themean fluorescence intensity, was
assigned to each sample. For each sample, the FI of the control containing
bacteria and complement only was subtracted, giving a final fluorescence
index minus complement-only control (FI#C=) value for each serum
sample, whichwas used as ameasure of antibody-dependent complement
deposition on the bacterial surface. Antibody-independent C3b/iC3b de-
position was similar between strains except for the serotype II isolate,
which showed greater FI values. Data from each day were normalized to
the C3b/iC3b bound to the preactivated zymosan control to account for
day-to-day variation within the assay.
Each serum sample was analyzed in the antibody-mediated comple-
ment deposition assay (CDA) against each of the five GBS serotypes cho-
sen. Each serum sample was analyzed in duplicate, and if the coefficient of
variance (%CV) between the two replicates was $35%, then the serum
was analyzed again. If the repeat FI#complement values were not within
50% of each other, then the serum was subjected to a further repeat anal-
ysis. If the repeats were within 50% of each other, the two C= values were
averaged; this was also the case if the analysis was repeated a third time. If
all three repeats were not within 50% of each other, then the sample was
given a not determined (ND) value for FI#C=. Graphs include all data
except the samples that were assigned ND, unless otherwise stated.
Clinical data analysis and statistics.Clinical data were obtained from
the mothers enrolled in the study and the neonates (18). These data in-
cluded GBS carriage status of the mother, ethnic group, past obstetric
history, recent antibiotic exposure, and any complications occurring dur-
ing birth. Infants were also visited at 7 and 28 days postbirth and at un-
planned sick visits, and the health of the neonate was checked specifically
for signs of neonatal sepsis. All graphs were drawn in GraphPad Prism 6
(GraphPad Software, Inc.). Reverse cumulative distribution curves for
CDA data were prepared as described by Reed et al. (20). The effects of
clinical parameters on antibody-mediated C3b/iC3b deposition were
evaluated using one-way analysis of variance (ANOVA).
RESULTS
Complement deposition assay. The CDA was optimized for in-
cubation times, blocking buffer formulation, IgG-depleted hu-
man plasma concentration, shaking speed, bacterial concentra-
tion, and serum dilution. Reproducibility of the CDA was
measured using a panel of 1 rabbit and 13 human sera against a
serotype II strain. Intra-assay precision (three assays performed
on 1 day) and interassay precision (one assay performed on 3
separate days) returned mean coefficients of variance of 22% and
26%, respectively. Interassay and complement variations over
time were controlled by normalizing all data to the fluorescence
index obtained with activated zymozan-complement controls,
which were included in each assay. Over 67 assays, the mean stan-
dard deviation of FI for the zymozan controls was 8,830 (coeffi-
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cient of variance, 31.6%). Linearity of the assay was assessed using
positive-control human sera (kind gift from Carol Baker), and it
was shown to be highly linear, with a mean R2 of 0.96 for the five
serotypes tested.
Antibody-mediated C3b/iC3b deposition by paired mother
and cord serum samples. Antibody-mediated C3b/iC3b deposi-
tion onto GBS isolates of serotypes Ia, Ib, II, III, and V for each
serum sample was evaluated using high-throughput flow cytom-
etry. A total of 1,045 serum samples were analyzed: 520 from
mothers and 525 associated cord samples (5 sets of twins). Car-
riage and clinical data relating to the mothers and neonates are
reported in Turner et al. (18). The GBS isolates were selected to
represent the two most prevalent serotypes (II and Ia), two sero-
types of medium prevalence (III and V), and one serotype of low
prevalence (Ib) in this region. A value (fluorescence index ob-
tained with test serum minus complement-only control value
[FI!C=]) of C3b/iC3b deposition was assigned to each serum
sample against each serotype tested. Sera with C3b/iC3b deposi-
tion values below the limit of detection of the assay (FI!C=,
"2,000) were assigned a nominal FI!C= value of 1,000 for data
analysis. In addition, sera giving nonreproducible FI!C= values in
duplicate assays were recorded as not determined (ND) and ex-
cluded from the analysis. The number of sera assigned an FI!C=
value of 1,000 or ND varied among the GBS serotypes tested (Ta-
ble 1).
Reverse cumulative distribution curves of antibody-mediated
C3b/iC3b deposition observed against each serotype with mother
and cord serum samples were compared (Fig. 1A). In the 549
mothers originally enrolled in the study, a carriage rate of 12%
(n# 66) was determined using culture- and PCR-based methods
(18). GBS serotype II was themost frequently carried, followed by
serotypes Ia, III, V, and Ib. The level of antibody-mediated C3b/
iC3b deposition observed against each serotype in the whole co-
hort corresponded with the carriage findings, with the highest
number of sera showing measurable C3b/iC3b deposition to se-
rotype II, followed by serotype Ia, serotype III, serotype V, and
serotype Ib.
Reverse cumulative distribution curves were also used to com-
pare the distribution of antibody-mediated C3b/iC3b deposition
in mother and cord serum samples separately for each serotype
(Fig. 1B). Antibody-mediated C3b/iC3b deposition levels for se-
rotypes II and Ia were clearly higher in the cord samples than in
samples from themothers (P# 0.009 andP# 0.037, respectively).
This trend was observed for serotypes III, V, and Ib, but these
differences were not significant (P $ 0.05). The same patterns
were observed when geometric mean C3b/iC3b depositions were
compared for the mother and cord data sets for each serotype
(Fig. 2).
Although GBS carriage was only detected in 12% of mothers,
antibody-mediated C3b/iC3b deposition was above the lower
limit of detection in 97% of cord samples and 92% of mother
samples to at least one serotype tested, as shown in Fig. 3. More-
over, 7% of cord samples and 4% of mother samples contained
antibodies thatmediated C3b/iC3b deposition to all five serotypes
tested. The percentages of individuals with antibody-mediated
C3b/iC3b deposition to !1 strain with FI!C= values of $5,000,
$10,000, and$20,000 are also presented, with fewer individuals
possessing CDA activity at these higher levels. However, there is a
greater divergence between values obtained for mother and cord
samples as the cutoff value is increased.
Association of clinical data with antibody-mediated C3b/
iC3b deposition. In this cohort, no neonates were found to have
early-onset disease (EOD) due to group B streptococcal infection.
Two neonates born to carriage-positive mothers showed signs of
EOD, but GBS was not identified as the causative agent. Thus, it
was not possible to evaluate the level of protective antibody-me-
diated complement deposition required to prevent disease.
The effects of a number of other clinical parameters on levels of
antibody-mediated C3b/iC3b deposition were evaluated by one-
way ANOVA. These included the mother’s age, number of previ-
ous pregnancies, neonate’s gestational age, and use of antibiotics.
None of these parameters had a significant effect (P$ 0.05) on the
functional antibody levels in mother and cord samples in this
study (data not shown). Sera from babies born at "37 weeks’
gestation did not show lower functional antibody levels to any of
the five GBS serotypes tested (data not shown).
GBS carriage was determined for each mother at the time of
birth by culture of vaginal and rectal swabs (18). No carriage data
were obtained from the neonate. For each serotype, antibody-
mediated C3b/iC3b deposition in samples frommothers that car-
ried GBS at the time of birth and their neonates was compared to
that of mothers and neonates where GBS carriage was not de-
tected. The antibody-mediated complement deposition in the
cord samples from neonates with mothers carrying GBS serotype
II was significantly higher (P " 0.001) than that determined in
cord samples taken from neonates born to mothers that did not
carry serotype II GBS (Fig. 4). A similar trend was observed when
comparing sera from mothers who carried serotype Ia GBS and
their neonates with samples from noncarriage mothers, shown in
Fig. 5. This did not reach statistical significance due to the low
number of mothers carrying this serotype. No significant differ-
ences were determined between mother and cord serum samples
against serotypes III, V, and Ib, possibly due to the small number
of mothers carrying these serotypes (18).
DISCUSSION
We developed a flow cytometry assay that measures antibody-
mediated deposition of complement components (C3b/iC3b)
that are required for opsonophagocytosis onto the surface of GBS
serotypes Ia, Ib, II, III, andV.Maternal antibodies toGBS capsular
polysaccharides have been shown to protect infants from early-
onset GBS disease (21, 22), with opsonophagocytic killing the
likely effector mechanism (15, 23). Opsonophagocytosis assays
were developed for a range of bacteria (24–27) and have been
widely used to assess immune responses to pneumococcal vac-
TABLE 1 Antibody-mediated C3b/iC3b deposition values above or
below the lower limit of detection (FI!C=" 2,000) or not determined








Ia 56.6 (605) 34.6 (370) 8.7 (93)
Ib 26.7 (285) 72.2 (771) 1.1 (12)
II 71.2 (760) 22.8 (244) 6.0 (64)
III 38.7 (413) 53.4 (570) 8.0 (85)
V 42.6 (455) 53.6 (572) 3.8 (41)
a n# number of samples analyzed. FI!C= is the fluorescence index value obtained with
the test serum minus the C3b/iC3b fluorescence obtained with the control containing
bacteria and complement only.
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FIG 1 (A) Reverse cumulative distribution (RCD) curves show distribution of antibody-mediated C3b/iC3b deposition levels against GBS serotypes Ia (n !
975), Ib (n ! 1,059), II (n ! 1,007), III (n ! 986), and V (n ! 1,030) in serum samples taken from mothers and umbilical cords. (B) RCD curves show
antibody-mediated C3b/iC3b deposition levels in mother and cord samples separately against GBS serotypes Ia (mother, n! 497; cord, n! 478), Ib (mother,
n! 535; cord, n! 521), II (mother, n! 505; cord, n! 499), III (mother, n! 500; cord, n! 483), and V (mother, n! 518; cord, n! 509). FI-C=, fluorescence
index minus complement only.
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cines where a role in protection was demonstrated (28–30). How-
ever, these assays rely on a source of phagocytic cells, such as fresh
human peripheral blood mononuclear cells (25, 27, 31) or differ-
entiated HL60 cells (29, 30), and day-to-day variability in these
cells can affect assay performance (32). The interaction of com-
plement proteins with a number of pathogens, includingNeisseria
meningitidis (33) andHaemophilus influenzae (34), has been stud-
ied in detail and is key in protecting against disease. Complement
interactions with Streptococcus pneumoniae are thought to be im-
portant, with individuals deficient in classic pathway components
having increased susceptibility to disease (35) and serotypes with
resistance to C3b/iC3b opsonization demonstrating greater inva-
sive capacity (36). The potential role of opsonophagocytosis in
protection fromGBSdiseasewas demonstrated using viable count
assays that use log reduction in CFU determination as a primary
readout (37–39).
FIG 2 Geometric means of antibody-mediated C3b/iC3b deposition levels in
mother and cord samples against serotypes Ia, Ib, II, III, and V GBS (n! the
number of samples included in each group). Data do not include the values
that were not assigned an FI"C= value. Bars represent 95% confidence inter-
vals.
FIG 3 Percentages of mother and cord samples that show antibody-mediated C3b/iC3b binding against !1 GBS strain tested using a cutoff FI"C= value of
#2,000 (A),#5,000 (B),#10,000 (C), and#20,000 (D). Samples that were assigned a not-determined value were classified as not havingmeasurable functional
antibody levels along with the samples assigned an FI"C= value of 1,000. Cord, n! 525; mother, n! 543.
FIG 4 Box plot shows the effect of serotype II carriage on antibody-mediated
C3b/iC3b binding to serotype II GBS in sera frommother and cord pairs taken
frommothers who were carriage positive (serotype II only) versus those from
mothers who were carriage negative. **, P$ 0.001.
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In this study, a complement deposition assay was utilized as a
possible surrogate for OPA. This flow cytometric assay measures
the antibody-dependent deposition of the complement opsonins
C3b/iC3b onto the surface of whole bacteria. This assay uses
smaller volumes of test sera than OPKA and fOPA yet measures
the total antibody-dependent complement deposition mediated
by all anti-polysaccharide and anti-protein antibodies, including
immunoglobulins other than IgG.Use of this single-dilution assay
enables the screening of a large number of samples in a relatively
short time. The assay uses fixed bacteria, which allowed a single
batch of bacteria for each serotype to be used for the study, thus
avoiding assay variability caused by growth-to-growth variation.
A total of 1,068 sera were analyzed against five GBS serotypes
using the CDA, and antibody-mediated C3b/iC3b deposition was
determined in mother and cord pairs from samples taken at the
time of birth. Within this cohort of 549 mothers, none of the
neonates developed GBS disease; therefore, it was not possible to
determine the level of antibody-mediated C3b/iC3b deposition
required to prevent disease. However, sera from neonates born to
GBS serotype II carriage-positivemothers had significantly higher
antibody-mediated complement deposition levels against sero-
type II GBS than sera from those born to mothers who were not
carriers of serotype II. Coupled with the absence of invasive dis-
ease in this population, this may indicate that neonates at risk
(born to carrier mothers) had adequate levels of antibodies to
prevent disease. Greater antibody-mediated C3b/iC3b deposition
in neonates born to carriermothers was also observed for serotype
Ia and was not observed for the other three serotypes tested likely
due to the small numbers of carrier mothers. This phenomenon
was observed previously, with infants born to GBS-colonized
mothers having antibody concentrations to a GBS surface protein
(Sip) that were higher than those found in infants born tomothers
who had no colonization (40).
Antibody-mediated C3b/iC3b deposition above the lower
limit of detection to at least one serotype was observed in 97% of
cord samples and 92% of mother samples, with 7% of cord sam-
ples and 4% of mother samples containing antibodies that medi-
ateC3b/iC3b deposition to all five serotypes tested. As only 12%of
mothers were found to be carriers of GBS at the time of birth, this
prevalence is greater than expected and may indicate that broad
immunity is generated by repeated transient episodes of carriage
of different GBS serotypes. No studies have evaluated the length of
carriage of GBS, which may vary depending on the geographic
region and ethnic population. The high proportion of individuals
with functional anti-GBS antibodies observed in this population
may explain the low incidence of GBS neonatal disease in this
geographic region, with Southeast Asia showing some of the low-
est rates of neonatal GBS disease (18, 41, 42). This requires further
study of invasive disease epidemiology and antibody prevalence.
As only 32/525 infants in the study were!37 weeks’ gestation,
we expected consistently higher geometric mean antibody-medi-
ated C3b/iC3b deposition levels in the cord samples than in sam-
ples from mothers due to the active transfer of IgG in the third
trimester (43, 44). For the two most prevalent serotypes, the cord
samples indeed showed greater complement deposition than the
samples from mothers. However, in the serum samples from
mothers, IgM may also contribute to the complement deposition
observed and would not have been transferred to the neonates,
which may explain why higher neonatal/maternal complement
deposition ratios were not seen for the three least-carried sero-
types.
Serum samples from premature and term neonates were com-
pared in this study, but no difference was seen in complement
deposition mediated by samples from the two groups. Prematu-
rity was previously shown to affect antibody levels that are trans-
ferred from mother to baby (43). However, in this cohort, no
neonates were born severely premature, since mothers were en-
rolled when already 28 to 30 weeks pregnant, and the low number
of neonates born within this group (n " 32) may lack statistical
power. In addition, antibody transfer occurs in the third trimester
(!27 weeks’ gestation), which may be why we saw no difference
between the neonates born prematurely (!37 weeks) and those
born at term.
The antibody-mediated complement deposition assay is a very
useful tool for assessing large numbers of sera against multiple
serotypes/strains. It could potentially be used to assess why there
are different incidences of disease in different ethnic groups and
geographic regions. For instance, in the United States, a 3-fold-
higher risk of GBS infection (late onset) was observed in the Afri-
can American community, with an incidence of 0.42/1,000 live
births versus an incidence of 0.11/1,000 live births in the nonblack
community (6), despite presumably having the same circulating
GBS strains. This has also been observed in southern Israel, where
the Bedouin Arab population has a GBS EOD incidence of 0.07/
1,000 live births, whereas the Jewish population has an incidence
of 0.35/1,000 live births (45). It may be that in these higher-inci-
dence populations, lower concentrations of functional antibodies
are present in mothers, resulting in higher neonatal disease rates.
Disease rates also vary in different geographic regions, with Africa
thought to have the highest incidence of disease, followed by the
Americas, Europe, and Southeast Asia (46). Geographic differ-
ences were also observed in England (0.72/1,000 live births), Scot-
land (0.42/1,000 live births), and Northern Ireland (0.9/1,000 live
births) (9). Currently, little information is available to help under-
stand these differences and why they occur to aid the rational
introduction of a GBS vaccine or other therapy.
This study has opened up the potential to evaluate the levels of
FIG 5 Box plot shows the effect of serotype Ia carriage on antibody-mediated
C3b/iC3b binding to serotype Ia GBS. Comparison of functional antibody
levels was done by comparing the mother and cord pairs taken from mothers
who were carriage positive (serotype Ia only) versus those from mothers who
were carriage negative.
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antibody-mediated complement deposition against different GBS
serotypes in large-scale seroepidemiological studies. Although the
goal of evaluating the antibody-mediated complement deposition
required to prevent disease was not attained in this study, this
research has provided a baseline for future studies. This assay will
enable some of the key unanswered questions, for instance, why
different populations show different incidences of disease, to be
studied. Use of this and other immunoassays in efficacy trials of
new GBS vaccines may identify a correlate of protection that will
facilitate vaccine development and evaluation.
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a  b  s  t  r  a  c  t
Invasive  Group-B  streptococcal  (GBS)  disease  is a leading  cause  of  infant  mortality  and  morbidity  world-
wide.  GBS  colonises  the maternal  rectum  and  vagina  and  transmission  of  bacteria  from  a colonized  mother
to her  infant  at birth  is  an  important  risk  factor  for GBS  disease.  GBS  disease  has  also  been  associated
with  case  reports  of  transmission  via  infected  breast  milk  raising  questions  about  mode  of acquisition  and
transmission  of  this  enteric  pathogen  and  the  development  of  neonatal  disease.  However,  most  breast-
fed  infants  remain  unaffected  by  GBS  in  breast  milk.  Mechanisms  associated  with  transmission  of  GBS
in  breast  milk  and  potential  factors  that  may  protect  the  infant  from  transmission  remain  poorly  under-
stood.  Understanding  factors  involved  in protection  or transmission  of  GBS  infection  via breast  milk  is
important  both  for  premature  infants  who  are  a high-risk  group  and  for infants  in  the  developing  world
where  breastfeeding  is  the  only  sustainable  infant  feeding  option.  In this review  we discuss  the  proposed
mechanisms  for GBS  colonization  in breast  milk  on  one  hand  and  its  immune  factors  that  may  protect
from  transmission  of  GBS  from  mother  to infant  on  the  other.  Innate  and  adaptive  immune  factors,  includ-
ing  serotype-specific  antibody  and  their significance  in the  prevention  of infant  disease  are  presented.  We
further report  on  the  role of  human  oligosaccharides  in  protection  from  invasive  GBS  disease.  Advances
in  our  knowledge  about  breast  milk  and  immunity  in  GBS  disease  are  needed  to  fully  appreciate  what
might  mitigate  transmission  from  mother  to  infant  and  protect  neonates  from  this  devastating  disease
and  to contribute  to the  development  of novel  prevention  strategies,  including  maternal  immunization
to  prevent  infant  disease.
©  2014  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
Streptococcus agalactiae (Lancefield Group B streptococcus; GBS)
was first described as a cause of bovine mastitis by Nocard and
Mollereau in 1887 [1]. Lancefield and Hare subsequently identified
GBS in vaginal swabs in 1935 [2] and in 1938 Fry described three
fatal cases in post-partum women [3]. Reports of neonatal disease
from GBS were sporadic until the early 1960s when GBS became
recognized as a leading cause of early neonatal sepsis in the USA
[4]. By the 1970s it had become the dominant pathogen in the early
neonatal period [5]. By the early 1980s GBS had become the most
common cause of neonatal sepsis and meningitis in a number of
developed countries [6–8]. In the past five years, late-onset (LO)
GBS disease has been associated with case reports of transmission
∗ Corresponding author at: Wellcome Trust Centre for Global Health Research,
Norfolk Place, London, UK. Tel.: +44 207594 2063.
E-mail addresses: kirstyledoare@gmail.com, k.mehring-le-doare@imperial.ac.uk
(K. Le Doare), b.kampmann@imperial.ac.uk (B. Kampmann).
via infected breast milk [9] raising questions about mode of acquisi-
tion and transmission of this enteric pathogen and the development
of neonatal disease.
Although GBS is not just a neonatal disease, the disease inci-
dence and severity is highest during the first 90 days of life. Early
onset (EO) GBS disease (disease presenting in the first six days of
life) accounts for approximately 60–70% of all GBS disease. GBS
serotypes Ia, Ib, II, III and V are responsible for most EO disease
[10,11]. In contrast, serotype III predominates in LO disease, which
may be acquired perinatally, nosocomially or from the community.
[12]
In the USA EO disease rates have declined from 1.4 per 1000
live births in 1990 [13] to at 0.28 per 1000 live births in 2012 [14]
mainly attributed to the implementation of universal screening for
GBS rectovaginal colonization in pregnant women and intrapartum
antibiotic prophylaxis. However, the incidence of LO disease has
remained static at between 0.3 and 0.4 per 1000 births since 1990
[14]. This amounts to 28,100 cases and 1865 deaths annually in
the USA [14]. Although the epidemiology of GBS in resource-rich
http://dx.doi.org/10.1016/j.vaccine.2014.04.020
0264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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countries is well documented, its contribution to the burden of
neonatal infection in low/middle income countries has proved
more difficult to assess. GBS has been reported as the predomi-
nant cause of neonatal sepsis in South Africa and Kenya [15–17]
as well as an important cause of meningitis in Malawi and Kenya,
but Asian studies have reported a much lower incidence [18–20].
A recent systematic review reported that the overall incidence of
GBS in resource-poor settings ranged between 0 and 3.06 per 1000
live births [21].
GBS colonizes the rectum and vagina, and maternal colonization
is a pre-requisite for EO disease and a risk factor for LO [22,23]. In
resource-rich countries an estimated 20–30% of pregnant women
are colonized with GBS [23,24], approximately 50% of their babies
become colonized and 1% progress to develop invasive disease. EO
disease may  occur rapidly; signs of sepsis are evident at birth or
within 12 h in over 90% of cases (98% within the first 12 h) [12].
Despite its rarity, LO disease, mostly presenting as meningitis, has
devastating long term consequences in survivors with up to 50%
suffering severe neurological sequelae [25].
It has been suggested that GBS initially colonizes the infant’s
oropharyngeal mucosa when contact with maternal vaginal secre-
tions occur at the time of birth [26]. Butter and DeMoor
demonstrated GBS in the nose and throat of infants at the same time
as GBS was cultured from the mother’s breast milk [27]. Fileron et al.
reviewed cases of LOGBS disease associated with GBS in breast milk
and found 48 LOGBS disease cases between January 1977 and March
2013 of which four had no other positive culture from mother or
infant other than GBS-contaminated breast milk. [9].
Therefore, there appears to be a dichotomy between cases of
LO disease through infected breast milk and the potential bene-
fits of the components of breast milk which protect the majority of
infants from invasive disease. The underlying mechanisms of GBS
transmission or protection through breast milk, are not fully under-
stood, but are important to elucidate, particularly in the context
of premature infants who are a high risk group and for infants in
the developing world where breastfeeding is the only sustainable
infant feeding option. In this review we focus on the peculiarities
of GBS that may  aid transmission in breast milk and the role of
immune parameters such as antibody in breast milk on the other
hand that may  help protect the breastfed infant from GBS disease.
2. Breast milk as vector of transmission of GBS
2.1. GBS in breast milk
Few studies have identified presence of GBS in breast milk, and
methodological differences make comparisons difficult [28–32].
Low incidence is described in mothers of extremely preterm infants
of 0.4% [31] and term infants of 0.82%. Higher incidence in raw milk
ranged from 3.5% [30] to 10% [29] in donor breast milk. However,
the concurrent incidence of GBS colonization in these mothers and
the effect of intrapartum and postpartum antibiotic treatment were
unknown.
The variety of delivery, treatment and storage methods of breast
milk offers potential for GBS contamination. Human breast milk
may  contain 103 to 109 cfu/mL of GBS at any point, representing a
reservoir of potential infection for the neonatal gut [33]. Breast milk
directly from the mother (either through natural breast feeding or
as expressed breast milk) is given raw and is rarely cultured in cases
of neonatal infection. Expressed breast milk and bank milk may
be frozen, which affects immune components and bank milk may
also be pasteurized. Pasteurization is thought to eradicate impor-
tant viral and bacterial infections [34] but also depletes milk of the
majority of its cellular components and immunoglobulins [35] and
may  increase the bacterial growth rate [36].
Very recently, best practices on the use of breast milk in the
context of prevention of GBS neonatal disease have been proposed,
including the search for GBS in milk at the time of recurrent GBS
neonatal disease and in cases of mastitis in mothers of high-risk
preterm neonates admitted to neonatal intensive care units [37].
For these neonates, microbiological control of raw milk has also
been proposed in the absence of mastitis [37]. However, the best
strategy has yet to be developed as it does not appear that pasteur-
izing maternal milk changes the overall incidence of late onset GBS
disease in preterm infants [38]. In a recent review article of cases
of late onset GBS disease from breast milk, GBS was  found in 0–2%
of raw milk samples and 1.4% of pasteurized milk samples [9].
2.2. Proposed methods of acquisition
Two  main mechanisms of acquisition have been proposed: fol-
lowing colonization of the neonatal oropharynx at the time of
birth, mothers may  develop colonization of the milk ducts through
ascending infection from the neonate, due to the retrograde flow
of milk associated with suckling. The infant is then reinfected as
the concentration of bacteria increases in the breast milk [39]. This
may  occur with or without mastitis depending on additional fac-
tors such as milk stasis and bacterial load [40]. In most of the case
reports of GBS disease associated with breast milk there is no sign
of maternal mastitis, indicating silent maternal duct colonization
[9]. However, recent studies in animal models and discovery of
lactobacilli in breast milk after oral administration suggest that
bacteria from the maternal digestive tract may also colonize the
breast. [41] It has also been suggested that lactic acid bacteria may
transfer from the mother’s gut to breast milk and through the milk
to the infant’s digestive tract [42]. The epidemiological relationship
between neonatal and maternal derived GBS isolates in breast milk
has been confirmed by polymerase chain reaction (PCR) [43]. How-
ever, it is not clear whether the LO disease relates to infected breast
milk or is a result of gut translocation from an already colonized
infant.
GBS may  infect the submucosa of the gastrointestinal tract
either through a defect in the epithelial cell layer, or by concomitant
infectious agents [33]. As neonatal gastric acid secretion is reduced,
more bacteria may  reach the intestinal mucosa. This is supported
by findings that preterm infants fed with contaminated maternal
milk via nasogastric tube have developed GBS disease [44].
3. Breast milk as vehicle of protection from GBS infection
3.1. Innate and adaptive immune properties of breast milk
Breast milk is the main source of non-pathogenic bacteria to the
infant gastrointestinal tract. Intestinal bacteria are one of the most
important stimuli for the development of mucosa-associated lym-
phoid tissue (MALT) in the neonatal small intestine [45] and pro-
duce organic acids that prevent growth of enteric pathogens. Addi-
tionally, breast milk and colostrum contain many components with
antimicrobial and immunomodulatory properties that are believed
to impair translocation of infectious pathogens [46]. Some of these
substances compensate directly for deficiencies in the neonatal
immune system and enhance survival of defense agents, including
secretory IgA (SIgA), lactoferrin, lysozyme, IFN-!; some adapt the
gastrointestinal tract to extrauterine life, i.e. epidermal growth fac-
tor [47]; some prevent inflammation or enhance specific-antibody
production, such as PAF-acetylhydrolase, antioxidants, interleukins
1, 6, 8, and 10, transforming growth factor (TGF), secretory leuko-
cyte protease inhibitors (SLPI), and defensin 1 [46]. Breast milk also
contains substantial amounts of intracellular adhesion molecule
1 and vascular adhesion molecule 1; low quantities of soluble
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S-selectin, l-selectin and CD14, which may  mediate differentia-
tion and growth of B cells [46]. Natural autoantibodies, thought to
be important in the selection of the pre-immune B cell repertoire
and in the development of immune tolerance, are also detected in
colostrum and in breast milk [48]. Recently, the beneficial effects of
human oligosaccharides in prevention of neonatal diarrhoeal and
respiratory tract infections have been highlighted [49,50].
Human breast milk is known to contain factors that can modu-
late toll-like receptor (TLR) signaling, including soluble TLR2, which
can competitively inhibit signaling through membrane TLR2 [51],
as well as a protein that inhibits TLR2-mediated and activates TLR4-
mediated transcriptional responses in human intestinal epithelial
and mononuclear cells by an as-yet-unknown mechanism [52]. It
has been speculated that reduced TLR2 responsiveness at birth may
facilitate the normal establishment of beneficial Gram-positive bifi-
dobacteria intestinal flora. Lipids present in human milk have been
shown to inactivate GBS in vitro, providing additional benefit to
protect from invasive infection at the mucosal surfaces [53].
4. Antibody in breast milk
Neonates have low levels of SIgA and SIgM [54] thus protection
from invasive pathogens at the mucosal surface relies on antibod-
ies in breast milk. As antibody in breast milk is produced following
antigenic stimulation of the maternal MALT and bronchial tree
(bronchomammary pathway) [55], these antibodies are targeted
to many infectious agents encountered by the mother both prior to
birth and during the breastfeeding period.
It is currently hypothesized that SIgA represents the crucial
primary protective component of breast milk [56,57]. SIgA pro-
tects against mucosal pathogens by immobilizing these, preventing
their adherence to epithelial surfaces, or by neutralizing toxins
or virulence factors. SIgA concentration is far higher in colostrum
(12 mg/ml) than in that found in mature milk (1 mg/ml). A breastfed
infant may  ingest around 0.5–1.0 g of SIgA per day [40].
5. The role of SIgA in breast milk
SIgA production is enhanced by Interleukin-6 (IL-6) whilst the
production of secretory components is enhanced by TNF-! and
TGF-" causes class switching towards B cells producing IgA [47],
all of which are present in breast milk.
SIgA antibodies present in breast milk are specific for numerous
enteric and respiratory pathogens. In studies from resource-poor
countries, breast milk-mediated protection against infections with
Vibrio cholerae, Campylobacter,  Shigella, Giardia lamblia and respira-
tory tract infections was significantly related to the content of SIgA
antibody in breast milk against these pathogens [58–60]. This could
support the hypothesis that similar protection could be obtained
from SIgA antibody in breast milk to GBS in a highly breastfed
population. However, maternal SIgA does not appear to enter the
neonatal circulation, [61] except in preterm infants, where inges-
tion of milk rich in IgA to respiratory syncytial virus (RSV) resulted
in increased serum IgA levels during the perinatal period [62], so
its effectiveness is limited to the mucosal surface.
SIgA is more resistant to proteolysis than other immunoglobu-
lins and is therefore able to function in the gastrointestinal tract
[46]. This could account for the finding that the faeces of breast fed
infants contains IgA by the second day of life, compared to 30% of
formula-fed infants, where IgA is only found in faeces by one month
of age [63].
Breast milk contains SIgA antibodies against bacterial-adhesion-
site-like pili [46,64]. SIgA antibody in milk blocks adherence of S.
pneumoniae and Haemophilus influenza to human retropharyngeal
cells [64] and casein in vitro [65]. The neutralizing capacity of milk
anti-poliovirus antibodies has also been reported [66,67].
The effect of third trimester maternal immunization with a sin-
gle dose of licensed quadrivalent meningococcal vaccine on the
potential protection of infants, including by breast milk demon-
strated elevated N. meningitidis-specific IgA antibodies in breast
milk up to six months post partum in vaccinated infants [68].
Similarly, in mothers who received pneumococcal polysaccharide
vaccine (PSV) during the third trimester, the geometric mean con-
centration of IgA in breast milk was significantly higher two months
postpartum than in women  who received conjugate H. influenzae
vaccine in the third trimester and remained higher at seven months
post partum. [69]
6. Group B Streptococcal antibody in breast milk
As described above, high levels of breast milk SIgA could
offer protection to neonates via interference of antibody with
the carbohydrate-mediated attachment of GBS to nasopharyngeal
epithelial cells. Through this mechanism, colonizing organism load
may  be reduced with a consequent reduction in morbidity and
mortality caused by GBS in the neonatal period [70].
In transition milk, low or moderate IgA antibodies to CPS type III
GBS, were detected in approximately 63% of a cohort of 70 Swedish
women [71]. In a study of IgG antibody concentration in transition
milk in 46 women  from the USA, Weisman and Dobson [70] found
concentrations of IgG to types Ia, II or III which were approximately
10% of those in maternal serum. Edwards et al. measured IgG and
IgA in breast milk to type III GBS in 18 women with high and low
antibody titers and found measurable levels of antibody in both
groups up to 2 months post-delivery [72]. Detectable levels of CPS
serotype III antibody in breast milk in women  correlated with con-
currently high levels in their serum. Whilst no studies demonstrate
a correlation between GBS-antibody levels in breast milk and infant
colonization, Berardi et al. report that GBS-positive breast milk is
associated with heavy infant colonization [73].
To determine the effect of maternal immunization with GBS
CPS-II and CPS-III antibody on postnatal protection from disease
a rodent model has been used, where increased survival in pups
exposed postnatally to breast milk with high titers of antibody
compared to low titers was  shown, supporting the beneficial added
effect of breast milk antibody following vaccination [74,75].
7. Human oligosaccharides
Oligosaccharides prevent cell adherence for S. pneumoniae [76]
and Escherichia coli (E. coli) [77]. Additionally, E. coli and Campy-
lobacter jejuni toxin can be neutralized by oligosaccharides [49,78]
and milk glycoconjugates prevent cell adherence of Vibrio cholera
and E. coli [79,80]. Taken together, these studies suggest that the
transfer of human milk oligosaccharides delivers real protection to
infants against many bacterial and viral infections.
GBS type Ib and II polysaccharides are of interest as they are vir-
tually identical to certain oligosaccharides present in human milk
[75,81,82] which raises the possibility of cross-reactivity with other
human glycoconjugates [83]. The results from murine models sug-
gest that these oligosaccharides may  act as receptor analogues that
anchor the bacteria in the mucosal layer and prevent cell adhesion
in the epithelial layer, thus preventing invasive disease.
8. Conclusion
Most neonatal infections occur via mucosal membranes in
the respiratory, gastrointestinal, and urinary tracts, yet there is
only limited protection at these vast mucosal surfaces during the
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neonatal period. Breast milk provides considerable amounts of
specific SIgA antibodies that are produced as a result of microbial
and food antigens the mother has previously encountered. Such
SIgA antibodies from breast milk provide protection to the neonate
at the mucosal surface. Breast milk additionally contains high
concentrations of non-specific protective molecules, such as lacto-
ferrin that has bactericidal, viricidal, and fungicidal properties.
Milk oligosaccharides might block adherence of microorganism at
the mucosal surface by functioning as receptor analogues.
There is increasing data from recent publications that enhanced
protection against diarrhea, respiratory tract infections, otitis
media and H. influenzae infections, as well as wheezing illness
may  persist for years after breastfeeding. However, the role
of breast milk antibody in protection from neonatal GBS dis-
ease remains poorly understood. Current research is evaluating
transport, persistence and function of GBS antibodies and other
immune-constituents in breast milk. These studies aim to identify
protective factors involved in the passive transfer of immune com-
ponents in breast milk and associated protection from colonization
and infant disease. Additionally, research correlating neonatal col-
onization with antibody levels in breast milk would provide insight
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a  b  s  t  r  a  c  t
Streptococcus  agalactiae  (group  B streptococcus  (GBS)),  remains  the  leading  cause  of neonatal  sepsis  and
meningitis  in many  countries  and an  important  cause  of  disease  in  pregnant  women,  immunocompro-
mised  adults  and  the  elderly.  Intrapartum  antibiotic  strategies  have  reduced  the incidence  of  early-onset
neonatal  GBS  where  applied,  but  have  had no  impact  on  late onset  GBS  infection  and  only  a  limited  impact
on disease  in  pregnant  women.  In low/middle  income  settings,  the  disease  burden  remains  uncertain
although  in  several  countries  of Southern  Africa  appears  comparable  to  that  of  high-income  countries.
Disease  may  be rapidly  fulminating  and  cases  therefore  missed  before  appropriate  samples  are  obtained.
This  may  lead  to  significant  underestimation  of  the  true  burden  and  be a particular  issue  in  many  African
and  Asian  countries;  comprehensive  epidemiological  data from  such  countries  are  urgently  required.
The  available  data  suggest  that  the  serotype  distribution  of  GBS  isolates  is  similar  in Africa,  Western
Pacific,  Europe,  the  Americas  and  the  Eastern  Mediterranean  regions  and  has  not  changed  over the  past
30 years.  Five  serotypes  (Ia, Ib,  II, III,  V) account  for the  majority  of  disease;  conjugate  vaccines  including
some  or all  of these  serotypes  therefore  hold  great  promise  for  preventing  this  important  disease.
© 2013 Elsevier Ltd. All rights reserved.
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1. Historical trends
Streptococcus agalactiae (Lancefield group B streptococcus; GBS)
was first described as a cause of bovine mastitis by Nocard and
Mollereau in 1887 [1]. Lancefield and Hare subsequently identified
GBS in vaginal swabs in 1935 [2] and in 1938 Fry described three
fatal cases in post-partum women. This was notable because all
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previous severe streptococcal infections in that setting had been
attributed to group A streptococcus [3]. Reports of neonatal disease
from GBS were sporadic until the early 1960s when GBS became
recognized as a leading cause of early neonatal sepsis in the USA
[4,5]. By the 1970s it had become the dominant pathogen in the
early neonatal period [6,7]. A similar (but slightly later) time trend
was noted for GBS meningitis in the UK [8]. By the early 1980s
GBS had become the most common cause of neonatal sepsis and
meningitis in a number of developed countries [9–11].
Human isolates of GBS express a capsular polysaccharide (CPS),
a major virulence factor that helps the microorganism evade host
defense mechanisms [4]. Isolates of GBS can be divided into ten CPS
serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII, IX) each antigenically and
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structurally unique. In 1974, Baker and Barrett demonstrated that
whilst all GBS serotypes were capable of causing neonatal infection,
type III isolates were significantly increased amongst infants with
GBS meningitis [12].
Bisharat et al.’s work on GBS multilocus sequence typing (MLST)
using a global collection of isolates demonstrated that capsular
serotype does not strictly follow sequence type (ST) and that a sin-
gle, bovine-derived ST (ST-17), appears to be overrepresented in
neonatal disease [13]. Further work from the USA [14] and the UK
[15] determined that ST-17 in types II and III GBS are closely related
to ancestral bovine isolates. This sequence type appears to be asso-
ciated with neonatal disease, irrespective of the capsular serotype,
but not with adult disease [15].
2. Infants
2.1. Early and Late onset infections
GBS disease is not restricted to newborns, but its greatest
impact, both in terms of severity and incidence, is in the neona-
tal period and up to the first 90 days of life. Early onset (EO) GBS
disease is usually defined as infection presenting in the first six days
of life and accounts for approximately 60–70% of all GBS disease.
GBS serotypes Ia, II, III and V are responsible for most EO disease
[16–18]. Maternal carriage of GBS in the gastrointestinal and/or
genital tracts is a pre-requisite for EO disease, vertical transmis-
sion occurring during or just prior to birth. In developed countries
an estimated 20–30% of pregnant women are colonized with GBS
[19,20], approximately 50% of their babies become colonized and
1% progress to develop invasive disease. Disease may  occur rapidly;
signs are evident at birth or within 12 h in over 90% of cases (98%
within the first 12 h) and presentation is typically with pneumonia
or sepsis [21].
In contrast, late-onset (LO) disease is caused predominantly by
serotype III, is acquired perinatally, nosocomially or from commu-
nity sources, and in up to 50% of cases presents with meningitis
[16,21–23]. Cases occurring later in infancy than 90 days are also
described, but rare, and generally associated with extreme prema-
turity [24–28].
2.2. The burden of infant GBS disease – high income countries
The burden of GBS disease can be defined in terms of its
incidence, morbidity and mortality. Multistate, population-based,
active surveillance in the USA in 1990 identified an EO disease rate
of 1.4 per 1000 live births and a LO rate of 0.4 per 1000 births [26].
This equated to 7600 cases and 310 deaths per year in the USA.
Both EO and LOGBS disease occurred at significantly higher rates
amongst African-American compared to Caucasian infants, as well
as amongst low-birthweight or preterm infants [26,27].
In the UK, a multi-center study carried out between 1977 and
1978 recorded an incidence of invasive GBS disease in infants < 2
months of age of 0.3 cases per 1000 live births [29]. Through the
late 1990s studies from different centers in England reported inci-
dence figures ranging from 0.6 to 1.2 cases per 1000 live births
[30–32]. In 2000–2001, national surveillance was  enhanced; the
overall incidence was 0.72 per 1000 live births (95% confidence
interval 0.66–0.78), 0.47 per 1000 (0.42–0.52) for EO disease and
0.25 per 1000 (0.21–0.28) for LO disease [21]. Regional variation
was marked; the incidence in Scotland was 0.42 per 1000 whilst
in Northern Ireland it was 0.9 per 1000 live births. As with other
studies, infants of low birthweight (<1500 g) were shown to have
the highest rates of GBS disease [21].
National population-based surveillance studies have defined
the incidence <3 months of age in a number of developed
countries including Portugal (2001–2005, 0.54/1000) [11], Finland
(1985–1994, 0.76/1000) [10] and Germany (2001–2003, 0.47/1000)
[9]. Hospital based surveillance studies (which may  be biased
towards higher risk pregnancies) have generally yielded higher
incidences such as in Australasia (EOGBS (<48 h of age): 2/1000 in
1991–1993, 1.3/1000 in 1993–1995, 0.5/1000 in 1995–1997) [33]
and Spain (EOGBS (<3 days of age): 1.1/1000, 1996–1997; 0.7/1000,
2000–2001) [34]. Edmonds et al. recently conducted a systematic
review to define the current global incidence of GBS disease in
infants under 3 months [35]. The analysis was confined to data
since the year 2000 and estimated an overall incidence of 0.53
(0.44–0.62) in the European region, 0.67 (range 0.54–0.80) in the
Americas and 0.15 (range −0.03 to 0.07) in Australasia. IAP was fre-
quent in developed countries and associated with lower incidence
figures; those countries reporting no use of IAP had a 2.2-fold higher
incidence of EOGBS compared with those reporting any use.
GBS disease is also associated with significant morbidity and
mortality. GBS meningitis, in particular, results in long term
neurodevelopmental impairment. Bedford et al. described 5-year
neurodevelopmental outcomes following an acute episode of
neonatal meningitis in 98 children, of whom 13% had severe, 17%
moderate and 18% mild disability at 5 years. Overall 50% of those
with GBS meningitis had neurodevelopmental impairment at 5
years of age [36]. A recent small series from the USA has shown sim-
ilar rates of sequalae (up to 44% with moderate–severe impairment)
[37].
Case fatality rates for GBS disease are estimated at between 9%
in Oxford (1990–1996) [30] and 15% in London (1990–1999) [38],
with a UK national figure of 10% in 2000–2001 [21]. In the USA
between 1993 and 1998 the quoted case fatality rates for EO and
LO disease were 4.7% and 2.8% respectively [39]. Case fatality rates
were significantly higher in premature infants (<33 weeks gesta-
tion) 15.2% vs. 6.4% for term infants (>37 weeks gestation), relative
risk of 6.7 in EOGBS (21, 39). Other national studies have revealed
case fatality rates of 6.6% in Portugal [11], 4.3% in Germany [9] and
8% in Finland [10]. Overall current case fatality rates by region as
estimated in the Edmond meta-analysis are 0.07 (range 0.04–0.1)
in Europe and 0.11 (0.06–0.16) in the Americas [35].
2.3. Risk factors
Numerous maternal, obstetric and neonatal factors have been
associated with or identified as risk factors for maternal GBS col-
onization, transmission of GBS from mother to baby, neonatal
GBS colonization or neonatal disease with GBS (both EO and LO).
Although some of these have provided useful insights into the
pathophysiology of perinatal GBS disease, many of them are inter-
related, studies have produced contradictory results and relatively
few factors are sufficiently robust or clinically relevant enough to
guide prevention strategies.
The gastrointestinal tract is the primary reservoir of GBS and
the source of vaginal colonization in women. Local hygiene or sex-
ual practices can increase the risk for vaginal colonization. Other
factors associated with maternal colonization include ethnicity
(women of Black race), use of tampons or intrauterine devices, obe-
sity, absence of lactobacilli in the gastrointestinal flora and preterm
delivery [40–42]. GBS bacteriuria during pregnancy is associated
with heavy colonization, a further risk factor for perinatal trans-
mission [43,44]. Mothers with GBS bacteriuria demonstrate a
higher incidence of adverse obstetric outcomes: habitual abortion,
intrauterine growth restriction, preterm labour, chorioamnionitis
and premature rupture of membranes [43].
Factors associated with an increased risk of neonatal coloniza-
tion include maternal colonization, male sex, Black race, prolonged
rupture of membranes, prematurity, low levels of maternal anti-
GBS antibodies and intrapartum fever. In one analysis, infants born
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to GBS-colonized women had a 29-fold increased risk for EO disease
compared to infants born to women who were not colonized [45].
In one case control study, prematurity (odds ratio 10.4, 95% confi-
dence interval 3.9–27.6), rupture of the membranes more than 18 h
before delivery (25.8, 10.2–64.8), rupture of the membranes before
the onset of labour (11.1, 4.8–25.9), and intrapartum fever (10.0,
2.4–40.8) were all significant risk factors for EOGBS [46]. Infants
born to mothers less than 20 years of age or of Black/Hispanic race
[27], with heavy genital GBS colonization [47], low levels of anti-
GBS capsular antibodies [48] or with a previous infant with EOGBS
disease [49] are all associated with a higher risk of EO disease.
Risk factors for LO disease are less well documented. Male sex,
Black race, maternal colonization and having a twin with LO dis-
ease are all associated with an increased risk for LOGBS disease
[22,27,28,50,51]. LO disease has been noted in children born to HIV-
infected mothers [52]. More recently it has become clear that the
major risk factor for LO disease is extreme prematurity [25–28].
2.4. Intrapartum antibiotics (IAP)
National strategies for targeting pregnant women  for IAP
include either risk-based [53] or screening based strategies
[54–56]. Following the publication of recommendations for both
risk-based and screening-based approaches, the incidence of
EOGBS disease in the USA decreased by almost 70% between 1996
and 1998 [39]. Death certificate analysis also documented a steeper
decline in EO deaths temporally associated with prevention imple-
mentation, without similarly steep declines in other causes of
deaths including LO deaths [57]. In an attempt to assess the relative
effectiveness of the two  strategies the CDC conducted a retrospec-
tive cohort study [58]. Adjusting for confounders, women who were
screened for GBS prenatally had a 50% reduced risk of delivering a
baby with GBS disease than did those exposed to the risk-based
strategy. In one study from the USA between 2002 and 2010 the
incidence of EO disease declined from 3.5 to 2.6 per 1000 admis-
sions, whilst LO disease has increased from 0.8 to 1.1 per 1000
admissions [59].
However, even strict and universal implementation of guide-
lines does not eliminate EOGBS disease; it can occur despite
administration of IAP, in infants of mothers who were negative on
screening, and where no risk factors are evident in labour [60–62].
In 2005 it was estimated that 1425 cases of EOGBS occurred in the
USA despite widespread use of IAP [63,64]. Most significantly, IAP
has no impact on LOGBS infection where the burden of disease is
substantial [64]. The majority of GBS meningitis occurs after the
first week of life so this particular burden remains; in the USA GBS
is now the most common cause of bacterial meningitis in children
less than 5 years of age [63].
2.5. Low and middle income countries
Although the epidemiology of GBS in the developed world is
well documented, its contribution to the burden of neonatal infec-
tion in low/middle income countries has proved more difficult to
assess. GBS has been reported as the predominant cause of neonatal
sepsis in southern Africa and Kenya [65–67] as well as an impor-
tant cause of meningitis in Malawi and Kenya, but Asian studies
have reported a much lower incidence [68–70]. In contrast, colo-
nization studies from these countries have reported only limited
variation in maternal GBS colonization rates, similar to those of
high income countries (Middle East/North Africa, 22%; Asia/Pacific,
19%; Sub-Saharan Africa, 19%; India/Pakistan, 12%; and Americas,
14%) [71].
Two systematic reviews of GBS incidence have attempted to
shed some light on this. Edmonds et al. showed that studies repor-
ting use of any IAP had a lower incidence of EO disease, but found
only one study from a middle-income country (South Africa) that
reported IAP use and no low-income countries reported IAP use.
Only 7 low-income countries reported data on GBS disease inci-
dence, only 3 for EOGBS disease (Kenya, Bangladesh, Malawi). The
mean incidence of EO disease was 0.43 (95% CI 0.37–0.49). Inci-
dence was highest in studies from Africa (0.53, 95% CI 0.15–0.92])
whilst studies from Southeast Asia reported the lowest incidence
(0.11, 95% CI 0.012–0.220). The incidence of LO disease was again
highest in Africa (0.71, 95% CI 0.38–1.04). The case fatality ratio
was three times higher in low-income countries (12.6%, 95% CI
10.8–14.9) than in high-income countries (4.6%, 2.1–9.1) [35].
Similar findings were reported by Dagnew et al., who  conducted
a systematic review and meta-analysis of GBS  disease focusing
on low and middle-income settings. They reported that the over-
all incidence of GBS in resource-poor settings ranged between 0
and 3.06 per 1000 live births [72]. Differences in incidence were
observed both between and within geographic regions. Variation
was greatest across sub-Saharan Africa, with studies from Nigeria
and the Gambia reporting lower incidence rates (0–0.17 per 1000
live births [73,74]) than studies from southern Africa (1.80–3.06 per
1000 live births [75,76]). Variation was evident across studies from
Latin America (0.39–1.15 per 1000 live births [77,78]), whereas
studies from Asia and the Middle East reported a lower GBS inci-
dence (0–0.26 per 1000 live births [68–70,79–83]). Reported case
fatality rates (median, 20%; range, 10–60%) also varied within and
between geographic regions [72].
Potential explanations for the variations highlighted in these
reviews include fundamental differences in disease epidemiology
due to differences in maternal GBS colonization, differences in
strain virulence [84], maternal and infant anti-GBS antibody levels
[74] or genetic susceptibilities. However, under-identification and
under-reporting of cases and deaths appears very likely in some
study settings, especially where it is difficult to access healthcare.
A substantial proportion of births in sub-Saharan Africa (42–65%),
India (53%) and Bangladesh (85%) for example, occur outside health
institutions. In contrast, South Africa, which reports one of the high-
est incidences, also has a high proportion of hospital-based births
(89%) [35]. Darmstadt et al. attempted to increase case ascertain-
ment by capturing births in the community. Of 919 community
assessments that resulted in a hospital referral only 54% complied
within two days and compliance was lower in infants aged 0–6
days. Of 259 neonatal deaths, 62% were never assessed by a health
worker and 59% occurred within the 1st two  days of life, consistent
with the time period of greatest risk for the development of GBS
sepsis [68].
Differences in microbiological and sampling techniques may
also contribute to differences in reported incidences [85]. Edmond
et al. searched articles for relevant indicators of this, such as the
proportion of specimens collected on the first day of illness or on
the day of birth or care-seeking and referral on day one of life, but
no data were available. Further, they sought to quantify labora-
tory techniques by searching for information on specimen volume,
transport conditions and culture techniques, but data were dis-
parate and could not be pooled [35]. Dagnew et al. also examined
methods of GBS sample isolation and identification. Thirteen stud-
ies, including all studies from South and Southeast Asia and the
Middle East used manual culture methods to isolate and identify
GBS and seven used automated methods (BACTEC system). GBS
incidence rates were shown to be higher amongst studies using
automated culture methods: 0.80–3.06 vs. 0–0.39/1000, suggesting
this as a further explanation [72].
2.6. GBS serotypes
In the USA and Europe, invasive GBS-serotypes are predomi-
nantly Ia, Ib, II, III and V [48,86–88] whilst a Gambian study reported
		 267	
	
K. Le Doare, P.T. Heath / Vaccine 31S (2013) D7– D12 D9
to GBS-colonized women had a 29-fold increased risk for EO disease
compared to infants born to women who were not colonized [45].
In one case control study, prematurity (odds ratio 10.4, 95% confi-
dence interval 3.9–27.6), rupture of the membranes more than 18 h
before delivery (25.8, 10.2–64.8), rupture of the membranes before
the onset of labour (11.1, 4.8–25.9), and intrapartum fever (10.0,
2.4–40.8) were all significant risk factors for EOGBS [46]. Infants
born to mothers less than 20 years of age or of Black/Hispanic race
[27], with heavy genital GBS colonization [47], low levels of anti-
GBS capsular antibodies [48] or with a previous infant with EOGBS
disease [49] are all associated with a higher risk of EO disease.
Risk factors for LO disease are less well documented. Male sex,
Black race, maternal colonization and having a twin with LO dis-
ease are all associated with an increased risk for LOGBS disease
[22,27,28,50,51]. LO disease has been noted in children born to HIV-
infected mothers [52]. More recently it has become clear that the
major risk factor for LO disease is extreme prematurity [25–28].
2.4. Intrapartum antibiotics (IAP)
National strategies for targeting pregnant women  for IAP
include either risk-based [53] or screening based strategies
[54–56]. Following the publication of recommendations for both
risk-based and screening-based approaches, the incidence of
EOGBS disease in the USA decreased by almost 70% between 1996
and 1998 [39]. Death certificate analysis also documented a steeper
decline in EO deaths temporally associated with prevention imple-
mentation, without similarly steep declines in other causes of
deaths including LO deaths [57]. In an attempt to assess the relative
effectiveness of the two  strategies the CDC conducted a retrospec-
tive cohort study [58]. Adjusting for confounders, women who were
screened for GBS prenatally had a 50% reduced risk of delivering a
baby with GBS disease than did those exposed to the risk-based
strategy. In one study from the USA between 2002 and 2010 the
incidence of EO disease declined from 3.5 to 2.6 per 1000 admis-
sions, whilst LO disease has increased from 0.8 to 1.1 per 1000
admissions [59].
However, even strict and universal implementation of guide-
lines does not eliminate EOGBS disease; it can occur despite
administration of IAP, in infants of mothers who were negative on
screening, and where no risk factors are evident in labour [60–62].
In 2005 it was estimated that 1425 cases of EOGBS occurred in the
USA despite widespread use of IAP [63,64]. Most significantly, IAP
has no impact on LOGBS infection where the burden of disease is
substantial [64]. The majority of GBS meningitis occurs after the
first week of life so this particular burden remains; in the USA GBS
is now the most common cause of bacterial meningitis in children
less than 5 years of age [63].
2.5. Low and middle income countries
Although the epidemiology of GBS in the developed world is
well documented, its contribution to the burden of neonatal infec-
tion in low/middle income countries has proved more difficult to
assess. GBS has been reported as the predominant cause of neonatal
sepsis in southern Africa and Kenya [65–67] as well as an impor-
tant cause of meningitis in Malawi and Kenya, but Asian studies
have reported a much lower incidence [68–70]. In contrast, colo-
nization studies from these countries have reported only limited
variation in maternal GBS colonization rates, similar to those of
high income countries (Middle East/North Africa, 22%; Asia/Pacific,
19%; Sub-Saharan Africa, 19%; India/Pakistan, 12%; and Americas,
14%) [71].
Two systematic reviews of GBS incidence have attempted to
shed some light on this. Edmonds et al. showed that studies repor-
ting use of any IAP had a lower incidence of EO disease, but found
only one study from a middle-income country (South Africa) that
reported IAP use and no low-income countries reported IAP use.
Only 7 low-income countries reported data on GBS disease inci-
dence, only 3 for EOGBS disease (Kenya, Bangladesh, Malawi). The
mean incidence of EO disease was 0.43 (95% CI 0.37–0.49). Inci-
dence was highest in studies from Africa (0.53, 95% CI 0.15–0.92])
whilst studies from Southeast Asia reported the lowest incidence
(0.11, 95% CI 0.012–0.220). The incidence of LO disease was again
highest in Africa (0.71, 95% CI 0.38–1.04). The case fatality ratio
was three times higher in low-income countries (12.6%, 95% CI
10.8–14.9) than in high-income countries (4.6%, 2.1–9.1) [35].
Similar findings were reported by Dagnew et al., who  conducted
a systematic review and meta-analysis of GBS  disease focusing
on low and middle-income settings. They reported that the over-
all incidence of GBS in resource-poor settings ranged between 0
and 3.06 per 1000 live births [72]. Differences in incidence were
observed both between and within geographic regions. Variation
was greatest across sub-Saharan Africa, with studies from Nigeria
and the Gambia reporting lower incidence rates (0–0.17 per 1000
live births [73,74]) than studies from southern Africa (1.80–3.06 per
1000 live births [75,76]). Variation was evident across studies from
Latin America (0.39–1.15 per 1000 live births [77,78]), whereas
studies from Asia and the Middle East reported a lower GBS inci-
dence (0–0.26 per 1000 live births [68–70,79–83]). Reported case
fatality rates (median, 20%; range, 10–60%) also varied within and
between geographic regions [72].
Potential explanations for the variations highlighted in these
reviews include fundamental differences in disease epidemiology
due to differences in maternal GBS colonization, differences in
strain virulence [84], maternal and infant anti-GBS antibody levels
[74] or genetic susceptibilities. However, under-identification and
under-reporting of cases and deaths appears very likely in some
study settings, especially where it is difficult to access healthcare.
A substantial proportion of births in sub-Saharan Africa (42–65%),
India (53%) and Bangladesh (85%) for example, occur outside health
institutions. In contrast, South Africa, which reports one of the high-
est incidences, also has a high proportion of hospital-based births
(89%) [35]. Darmstadt et al. attempted to increase case ascertain-
ment by capturing births in the community. Of 919 community
assessments that resulted in a hospital referral only 54% complied
within two days and compliance was lower in infants aged 0–6
days. Of 259 neonatal deaths, 62% were never assessed by a health
worker and 59% occurred within the 1st two  days of life, consistent
with the time period of greatest risk for the development of GBS
sepsis [68].
Differences in microbiological and sampling techniques may
also contribute to differences in reported incidences [85]. Edmond
et al. searched articles for relevant indicators of this, such as the
proportion of specimens collected on the first day of illness or on
the day of birth or care-seeking and referral on day one of life, but
no data were available. Further, they sought to quantify labora-
tory techniques by searching for information on specimen volume,
transport conditions and culture techniques, but data were dis-
parate and could not be pooled [35]. Dagnew et al. also examined
methods of GBS sample isolation and identification. Thirteen stud-
ies, including all studies from South and Southeast Asia and the
Middle East used manual culture methods to isolate and identify
GBS and seven used automated methods (BACTEC system). GBS
incidence rates were shown to be higher amongst studies using
automated culture methods: 0.80–3.06 vs. 0–0.39/1000, suggesting
this as a further explanation [72].
2.6. GBS serotypes
In the USA and Europe, invasive GBS-serotypes are predomi-
nantly Ia, Ib, II, III and V [48,86–88] whilst a Gambian study reported
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serotype-V predominance [84]. The recent global review of invasive
isolates showed that serotype III was the most frequently identi-
fied serotype in all regions with available data (48.9%), followed by
serotypes Ia (22.9%), V (9.1%), Ib (7.0%) and II (6.2%). There was lit-
tle change in ST distribution over the last 30 years [35]. There was
however, little data from low/middle income countries.
3. Pregnancy-associated GBS disease
The incidence of pregnancy-associated GBS disease in the USA
initially declined after the introduction of IAP strategies (0.29 per
1000 live births in 1993 vs. 0.11–0.14 per 1000 live births in 2005)
[87]. In a recent study the incidence was shown to be 0.02/1000
in non-pregnant women vs. 0.49/1000 (range 0.36–0.64) in post-
partum women [89]. This study highlighted that the majority of
pregnancy-associated disease actually occurred in the postpartum
period. The authors found that pregnant women had a relative
risk for GBS disease of 5.0 (95% CI, 2.9–8.7) compared with non-
pregnant women. The median age at onset was 28 years and half
of the cases were associated with infection of the upper genital
tract, placenta, or amniotic sac. Other manifestations included bac-
teremia without focus (31%), endometritis without foetal death
(8%), chorioamnionitis without foetal death (4%), pneumonia (2%),
and puerperal sepsis (2%). Amongst those for whom pregnancy out-
come was known (368/409, 90%), 61% had a spontaneous abortion
or stillborn infant, 30% had infants without apparent illness, 5% had
live-born infants who developed clinical infections, and 4% had
induced abortions. Most pregnancy-related cases (330/409, 81%)
occurred in the absence of additional underlying conditions; 79
occurred with at least one additional underlying condition or risk
factor including smoking, asthma, diabetes, obesity and alcohol or
drug abuse [89]. The serotypes causing maternal GBS appear to be
similar to those that cause EOGBS [90,91].
4. GBS in non-pregnant adults
Amongst adults, older age, black race, and underlying medical
conditions are associated with higher rates of invasive GBS dis-
ease [92–101]. Common presentations of GBS disease in adults
include skin and/or soft-tissue infection, bacteremia without focus,
pneumonia, and osteomyelitis; serious clinical syndromes, such
as meningitis and endocarditis are rare but are often associated
with considerable morbidity and mortality [93–97,100,101]. The
case fatality rate is markedly higher amongst adults than amongst
neonates [94–98,100]. In contrast to neonates and pregnant
women, disease incidence amongst non-pregnant adults increased
significantly in the USA between 1990 and 2007 [102]. Amongst
persons aged 15–64 years, incidence increased from 3.6 per 100 000
population in 1999 to 7.3 per 100 000 in 2007, a relative increase of
48% (95% CI, 32–65%); amongst those 65 years or older, incidence
increased from 21.5 per 100 000 to 26.0 per 100 000, a relative
increase of 20% (95% CI, 8–35%). These values translate to a 32% (95%
CI, 22–43%) increase in the overall incidence of adult disease, which
increased from 6.0 per 100 000 in 1999 to 7.9 per 100 000 in 2005.
The case-fatality rate decreased from 23.7% in 1990 to 7.5% in 2007
[102]. The proportion with known outcome that died was  highest
in the oldest age groups. Seasonal variability was evident, with dis-
tinct peaks occurring each year during the later summer months. In
contrast to pregnant women and neonates, in adult cases, serotype
V predominated, accounting for 31% of cases, followed by serotypes
Ia (24%), II (12%), and III (12%) [63]. Recently, however, a Portuguese
study found that serotype Ia was responsible for the majority of
invasive infections in all age groups [103].
The underlying medical conditions associated with invasive GBS
disease in non-pregnant adults include diabetes mellitus (41%),
heart disease (36%), and malignancy (17%). In one series, nearly
88% of adult cases had at least 1 underlying condition [100]. In
the USA between 1998 and 2007, the proportion of patients with
underlying diabetes increased significantly (from 36.5% to 44.4%),
although the proportion of patients with cancer, heart failure, and
atherosclerotic cardiovascular disease remained relatively stable
[101].
5. Discussion
GBS is the leading cause of neonatal sepsis and meningitis in
developed countries. It is also a recognized and increasing cause
of disease in adults in such countries, especially pregnant women,
the elderly and the immunocompromised. In resource-poor sett-
ings, however, the neonatal burden is less clear, although in some
countries may  be higher than in developed countries. The disease is
often rapidly fulminating and many cases may  be missed because
of difficulties with obtaining samples before babies die. This issue
is especially important in African and Asian countries. A failure to
diagnose cases in the community, sick babies that then fail to reach
healthcare facilities, inadequate culture methods, and widespread
antibiotic usage may  all lead to an underestimation of the GBS
burden. More high-quality studies are urgently needed in these
settings.
Comprehensive data on disease burden will enable appropri-
ate preventative strategies to be devised and implemented. GBS
vaccines in particular, hold great promise as they have the poten-
tial to prevent all neonatal GBS disease, early and late onset, to
avoid the issues around screening and intrapartum antibiotic use
and are likely to be the most cost effective approach of all. Available
data suggest that a conjugate vaccine incorporating five serotypes
may  prevent over 85% of global GBS disease in infants under three
months. Vaccine development is eagerly awaited.
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